


CLINICAL DATA UPDATE SYSTEM (CDUS)

Instructions and Guidelines

Version 3.0, Release 2
June 10, 2003

NCI CTEP Help Desk -
Telephone: (301) 840-8202
Fax: (301) 948-2242
E-mail: ncictephhelp@ctep.nci.nih.gov



BUILDING THE FUTURE
TOGETHER™

By Capital Technology Information Services, Inc.

Table of Contents

1. CLINICAL DATA UPDATE SYSTEM (CDUS) INSTRUCTIONS.....	1
1.1. OVERVIEW	1
1.2. WHO SHOULD SUBMIT DATA	1
1.3. WHAT DATA SHOULD BE SUBMITTED	1
1.3.1. Abbreviated CDUS Data Set	2
1.3.2. Complete CDUS Data Set.....	3
1.3.3. Trial Categories.....	3
1.3.3.1. Treatment Trials that include DCTD-Supplied Investigational Agents.....	3
1.3.3.1.1. Phase 1 – CTMS Monitored Trials that include DCTD-Supplied Investigational Agents.....	3
1.3.3.1.2. Phase 1 – Non-CTMS Monitored Trials that include DCTD-Supplied Investigational Agents.....	4
1.3.3.1.3. Phase 2 Trials that include DCTD-Supplied Investigational Agents	4
1.3.3.1.4. Phase 3 Trials that include DCTD-Supplied Investigational Agents	4
1.3.3.2. Treatment Trials that do not include DCTD-Supplied Investigational Agents	4
1.3.3.2.1. Cooperative Group and Research Base Trials.....	4
1.3.3.2.2. Non-Group (Cancer Center or other Institution) Trials.....	4
1.3.3.2.2.1. Approved NCI Grant which requires CDUS Reporting.....	4
1.3.3.2.2.2. Non-Group (Cancer Center or other Institution) Trials that do not include a DCTD-Supplied Investigational agent or NCI Grant	5
1.3.3.3. Non-Treatment Trials (pharmacokinetic, cytogenetics, etc.).....	5
1.3.3.3.1. Cooperative Group and CCOP Research Base Non-Treatment Trials.....	5
1.3.3.3.2. Non-Group (Cancer Center or other Institution) Non-Treatment Trials	5
1.3.3.4. DCP Sponsored CCOP Research Base Cancer Prevention and Control Trials (chemoprevention; bio-marker and early detection; symptom management; pain control; rehabilitation and continuing care; and quality of life)	5
1.4. WHEN DATA SHOULD BE SUBMITTED	6
1.4.1. Frequency.....	6
1.4.2. First CDUS Submission Date	6
1.4.3. Submission Duration	7
1.5. METHODS OF DATA SUBMISSION	7
1.5.1. CTEP FTP Site	7
1.5.2. CDUS Web Site.....	8
1.6. PROTOCOL CODE INFORMATION	8
1.6.1. Correlative Studies	8
1.6.2. Subgroups	9
1.6.3. Treatment Assignments (arm/dose levels)	9
2. DATA ELEMENT DESCRIPTIONS	10
2.1. GENERAL SUMMARY INFORMATION.....	10
2.1.1. Administrative.....	10
2.1.1.1. NCI Protocol Number	10
2.1.1.2. Protocol Title	10
2.1.1.3. Report Dates	10
2.1.1.3.1. Date Report Submitted.....	10
2.1.1.3.2. Cut-off Date for Data	10
2.1.1.3.3. Report Due Date	10
2.1.1.3.4. Protocol Activation Date.....	10
2.1.1.4. Primary (Lead) Institution/Group Code (CTEP ID)	11
2.1.1.5. Current Trial Status.....	11
2.1.1.6. Current Trial Status Date	11
2.1.1.7. Person Completing the Report.....	12

2.1.1.7.1.	Name	12
2.1.1.7.2.	Telephone Number	12
2.1.1.7.3.	Fax Number (optional)	12
2.1.1.7.4.	E-mail Address (optional)	12
2.1.1.8.	Additions or Changes Since the Last Report (Change Code)	12
2.1.1.9.	Principal Investigator	12
2.1.1.9.1.	Name	12
2.1.1.9.2.	Investigator Number	12
2.1.1.10.	Grant Information	12
2.1.1.11.	Total Accrual	13
2.1.1.11.1.	Total Planned Accrual	13
2.1.1.11.2.	Amended Planned Accrual	13
2.1.1.11.3.	Actual Accrual	13
2.1.1.12.	Accrual Rate (patients/month)	13
2.1.1.12.1.	Planned Accrual Rate	13
2.1.1.12.2.	Amended Accrual Rate	13
2.1.1.12.3.	Actual Accrual Rate	13
2.1.1.13.	Closure Date	14
2.1.1.13.1.	Planned Closure Date	14
2.1.1.13.2.	Amended Closure Date	14
2.1.1.13.3.	Projected Closure Date	14
2.1.2.	<i>SubGroups/Treatment Assignments</i>	14
2.1.2.1.	Subgroup Code	14
2.1.2.2.	Subgroup Description	15
2.1.2.2.1.1.	Patients Stratified by Disease	15
2.1.2.2.1.2.	Patients Stratified by Other Classification (e.g., prior therapy, age)	15
2.1.2.3.	Treatment Assignment (arm/dose level)	15
2.1.3.	<i>Correlative Studies</i>	15
2.1.3.1.	Correlative Study Identification (ID)	15
2.1.3.2.	Correlative Study Title (laboratory, pharmacokinetic or other correlative studies)	15
2.1.3.3.	Correlative Study Findings	16
2.1.3.3.1.	Patients Collected	16
2.1.3.3.2.	Patients Analyzed	16
2.1.3.3.3.	Samples Collected	16
2.1.3.3.4.	Samples Analyzed	16
2.1.3.3.5.	Correlative Study Findings or Conclusions	16
2.1.4.	<i>Phase I End Points and Phase I End Point DLTs</i>	16
2.1.4.1.	Subgroup Code	16
2.1.4.2.	Recommended Phase 2 Dose or Minimum Effective Dose	16
2.1.4.2.1.	Dose Limiting Toxicity (DLT)	17
2.1.4.2.1.1.	Subgroup	17
2.1.4.2.1.2.	Treatment Assignment	17
2.1.4.2.1.3.	DLT Type	17
2.1.4.2.1.4.	DLT (Adverse Event) Other, Specify	17
2.1.5.	<i>General Data Summary by Subgroup and/or Treatment Assignment (Trial Comments)</i>	17
2.1.5.1.	Subgroup/Treatment Assignment Code	17
2.1.5.1.1.	Adverse Event/Dose Modifications by Subgroup and/or Treatment Assignment	18
2.1.5.1.2.	Response by Subgroup and/or Treatment Assignment	18
2.1.6.	<i>Publications</i>	18
2.1.6.1.	Publication Identification (ID)	18
2.1.6.1.1.	Citation Identification (Medline UID)	18
2.1.6.1.2.	Full Citation	18
2.1.6.1.2.1.	Author Order and Name	18
2.1.6.1.2.2.	Title	18
2.1.6.1.2.3.	Journal	18
2.1.6.1.2.4.	Volume	19

2.1.6.1.2.5.	Year.....	19
2.1.6.1.2.6.	Publisher	19
2.1.6.1.2.7.	Pages	19
2.2.	PATIENT-SPECIFIC DATA.....	19
2.2.1.	<i>Patient Demographic Items</i>	19
2.2.1.1.	Patient ID	19
2.2.1.2.	Patient's Zip Code	19
2.2.1.3.	Patient's Country Code.....	19
2.2.1.4.	Patient's Birth Date.....	19
2.2.1.5.	Patient's Gender.....	20
2.2.1.6.	Patient's Race and Ethnicity	20
2.2.1.6.1.	Ethnicity Flag.....	20
2.2.1.6.2.	Race Code	20
2.2.1.7.	Patient's Method of Payment.....	21
2.2.1.8.	Date of Patient Entry	22
2.2.1.9.	Registering Group Code	22
2.2.1.10.	Registering Institution Code.....	22
2.2.1.10.1.	Non-Cooperative Group Studies.....	22
2.2.1.10.2.	Cooperative Group Studies	23
2.2.2.	<i>Patient Administrative Items</i>	23
2.2.2.1.	Treatment Status (Treatment On Study)	23
2.2.2.2.	Off Treatment Reason.....	23
2.2.2.3.	Date of Last Treatment	24
2.2.2.4.	Off Study Reason.....	24
2.2.2.5.	Off Study Date.....	24
2.2.2.6.	Subgroups	25
2.2.2.7.	Ineligibility Status.....	25
2.2.2.8.	Baseline Performance Status	25
2.2.2.9.	Prior Therapy	26
2.2.2.9.1.	Number of Prior Chemotherapy Regimens.....	26
2.2.2.9.2.	Prior Therapy Type (MedDRA Code)	27
2.2.2.10.	Patient's Disease Code	29
2.2.2.11.	Response Evaluation Status.....	29
2.2.2.12.	Baseline Abnormalities Flag.....	29
2.2.2.12.1.	Baseline Abnormality Type, Grade, and Other, Specify.....	29
2.2.3.	<i>Patient Treatment by Course</i>	30
2.2.3.1.	Course Identification	30
2.2.3.2.	Course Start Date	30
2.2.3.3.	Treatment Assignment.....	30
2.2.3.3.1.	Phase 1 Studies	30
2.2.3.4.	Treating Institution Code.....	31
2.2.3.4.1.	Non-Cooperative Group Studies.....	31
2.2.3.4.2.	Cooperative Group Studies	31
2.2.3.5.	Patient's Height	31
2.2.3.6.	Patient's Weight	31
2.2.3.7.	Patient's Body Surface Area.....	31
2.2.3.8.	Dose of the Investigational Agent Received by Patient.....	31
2.2.3.8.1.	Investigational Agent Administered	32
2.2.3.8.1.1.	Dose Modification (Change).....	32
2.2.3.8.1.2.	Total Dose of the Investigational Agent Administered per Course.....	32
2.2.3.8.1.3.	Dose Units.....	32
2.2.3.9.	Patient-Specific Adverse Event Reporting Requirements	32
2.2.3.9.1.	Patients Experiencing an Adverse Event During the Current Course of Therapy	34
2.2.3.9.2.	Patients Experiencing an Adverse Event	34
2.2.3.9.2.1.	Adverse Event Type.....	34
2.2.3.9.2.2.	Grade.....	35

2.2.3.9.2.3.	Adverse Event – Other, Specify	35
2.2.3.9.2.4.	Attribution	36
2.2.3.9.2.5.	Adverse Event Expedited Report	36
2.2.3.9.3.	Late Adverse Event	37
2.2.3.9.3.1.	Late Adverse Event Type, Grade, and Other, Specify	37
2.2.3.9.3.2.	Attribution	37
2.2.3.9.3.3.	Late Adverse Event Start Date	37
2.2.4.	Response of Patient's Malignancy	37
2.2.4.1.	Evaluable for Response	37
2.2.4.1.1.	Response (Category)	38
2.2.4.1.2.	Response (Observed Date)	38
3.	CDUS - DATA MODEL	40
4.	CDUS - SMART LOADER FILE FORMAT INSTRUCTIONS	41
4.1.	INTRODUCTION	41
4.2.	RELATION BETWEEN ENTITIES	41
4.3.	FILE FORMAT	42
4.3.1.	<i>COLLECTIONS Table</i>	42
4.3.2.	<i>CORRELATIVE STUDIES Table</i>	43
4.3.3.	<i>PUBLICATIONS Table</i>	43
4.3.4.	<i>AUTHORS Table</i>	44
4.3.5.	<i>PATIENTS Table</i>	44
4.3.6.	<i>PATIENT RACES Table</i>	45
4.3.7.	<i>PRIOR THERAPIES Table</i>	45
4.3.8.	<i>TREATMENT COURSES Table</i>	46
4.3.9.	<i>COURSE AGENTS Table</i>	46
4.3.10.	<i>BASELINE ABNORMALITIES Table</i>	47
4.3.11.	<i>ADVERSE EVENTS Table</i>	47
4.3.12.	<i>LATE ADVERSE EVENTS Table</i>	47
4.3.13.	<i>BEST RESPONSES Table</i>	48
4.3.14.	<i>TRIAL COMMENTS Table</i>	48
4.3.15.	<i>PHASE1 END POINTS Table</i>	49
4.3.16.	<i>PHASE1 END POINT DLTS Table</i>	49
5.	CDUS SMART LOADER SAMPLE FILE	50
6.	CDUS - VALID VALUES	51
7.	CDUS - SMART LOADER APPROVAL, DISAPPROVAL, AND CORRECTION PROCESS	55
7.1.	OVERVIEW	55
7.2.	DEFINITIONS FOR MANDATORY, REQUESTED, AND OPTIONAL	55
7.2.1.	<i>Mandatory Data Elements</i>	55
7.2.2.	<i>Requested Data Elements</i>	55
7.2.3.	<i>Optional Data Elements</i>	55
7.3.	DEFINITIONS FOR INCOMPLETE, INCORRECT, INAPPROPRIATE, AND INCONSISTENT	55
7.3.1.	<i>Incomplete Data</i>	56
7.3.2.	<i>Incorrect Data</i>	56
7.3.3.	<i>Inappropriate Data</i>	56
7.3.4.	<i>Inconsistent Data</i>	56
7.4.	CUMULATIVE DATA	56
7.5.	SUBMISSION RESULTS	57
7.5.1.	<i>Smart Loader Approval (Successful/Accepted)</i>	57
7.5.2.	<i>Smart Loader Disapproval (Rejection)</i>	57
7.6.	TYPES OF ERROR NOTICES	58
7.6.1.	<i>CDUS Rejection Notice</i>	58

7.6.2.	<i>CDUS Caution Notice</i>	58
7.6.2.1.	Correction Process for Caution Errors	58
7.6.2.2.	Responding to a Caution Notice	59
7.6.3.	<i>CDUS Cumulative Error Notice</i>	59
7.6.3.1.	Correction and Response Process for Cumulative Errors	59
7.7.	CDUS WARNING AND SUSPENSION LETTERS	59
8.	INTERPRETING THE CDUS ERROR REPORTS	60
8.1.	ERROR LOG REPORT	60
8.1.1.	<i>CDUS Error Log Report Column Headings</i>	61
8.1.1.1.	Date of Generation	61
8.1.1.2.	Protocol ID	61
8.1.1.3.	Load Number	61
8.1.1.4.	Load Date	61
8.1.2.	<i>Report Detail</i>	61
8.1.2.1.	Error ID	61
8.1.2.2.	Line Number	61
8.1.2.3.	Table Name	61
8.1.2.4.	Column Name	62
8.1.2.5.	Column Value	62
8.1.2.6.	Error Location	62
8.1.2.7.	Unique Identifiers	62
8.1.2.8.	Error Category	62
8.1.2.9.	Error Encountered	62
8.2.	ERROR DESCRIPTION REPORT	62
8.3.	SAMPLE REPORTS	63
9.	CDUS BUSINESS RULES	67
INDEX		72

Questions and Comments:

If you have any questions or comments regarding the Clinical Data Update System (CDUS), please contact the NCI CTEP Help Desk by telephone (301) 840-8202, fax (301) 948-2242, or e-mail at ncictephelp@ctep.nci.nih.gov.

Additional information regarding the CDUS is available on the CTEP Home Page (<http://ctep.info.nih.gov/>)

1. CLINICAL DATA UPDATE SYSTEM (CDUS) INSTRUCTIONS

1.1. OVERVIEW

The Clinical Data Update System (CDUS) is the primary resource of clinical trial data for the Division of Cancer Treatment and Diagnosis (DCTD) and the Division of Cancer Prevention (DCP). CDUS reports should be submitted for all DCTD and DCP sponsored trials (Phase 1, 2, and 3). This includes all DCTD sponsored Cooperative Group and CCOP Research Base treatment trials utilizing DCTD-supplied investigational agents and trials utilizing non-NCI agents (commercial or investigational); all DCTD grant funded non-Cooperative Group (Cancer Center or other institution) trials (if CDUS reporting is a grant requirement) utilizing non-NCI agents; all DCTD sponsored Cooperative Group and CCOP Research Base non-treatment trials (accrual > 100 pts.); and all DCP sponsored CCOP Research Base cancer prevention and control trials.

CTEP staff, in conjunction with external participants [e.g., Cooperative Groups, Cancer Centers, Food and Drug Administration (FDA), manufacturers], have made every attempt to define the minimum number of data elements needed to fulfill the regulatory, scientific, and administrative needs of the NCI. The amount of information required for submission to CTEP will vary depending on certain characteristics of the trial (see Section 1.3 for further details).

Specific details about CDUS reporting requirements can be found in the sections that follow.

1.2. WHO SHOULD SUBMIT DATA

For each protocol, the lead Group or Institution is responsible for submitting CDUS data.

Inter-Group/Multi-Institution Trials:

The lead Group or institution for a protocol is responsible for compiling and submitting CDUS data for all participants.

Cooperative Groups participating in pharmaceutical company sponsored studies:

An exception is made in this situation. The participating Cooperative Group will be considered the lead organization and an Abbreviated CDUS Data Set will be submitted quarterly. If multiple Groups are participating on a pharmaceutical sponsored study, then the lead Group will be responsible for compiling and submitting CDUS data for all Group participants.

1.3. WHAT DATA SHOULD BE SUBMITTED

Either an Abbreviated CDUS Data Set (containing the data elements found in Section 2.1.1 and Section 2.2.1) or a Complete CDUS Data Set (containing all CDUS data elements), will be required. CTEP has grouped data elements into three categories: Mandatory, Requested, and Optional. Please refer to Section 9 of this document for a complete listing of the business rules for more information regarding mandatory and requested data elements. **All data submissions must be cumulative.** The type and amount of data required from an investigator depends upon the following:

- The trial source (Cooperative Group and Community Clinical Oncology Program (CCOP) Research Base vs. non-Cooperative Group),
- Whether the trial utilizes a DCTD-supplied Investigational New Drug (IND),
- The phase of the trial, and
- If the trial is sponsored by DCTD or DCP.

1.3.1. ABBREVIATED CDUS DATA SET

The Abbreviated CDUS Data Set is limited to protocol administrative and patient demographic information.

An Abbreviated CDUS Data Set will include the following administrative data elements:

- NCI Protocol Number,
- Date Report Submitted,
- Cut-Off Date for Data,
- Current Protocol Status,
- Current Protocol Status Date,
- Person Completing the Report,
 - Name: Last Name^First Name^Middle Initial,
 - Telephone Number,
 - Fax Number (optional),
 - E-mail Address (optional), and
- Change Code.

See Section 2.1.1 for descriptions of the administrative data elements.

An Abbreviated CDUS Data Set will also include the following patient demographic data elements:

- Patient ID,
- Patient's Zip Code,
- Patient's Country Code,
- Patient's Birth Date,
- Patient's Gender,
- Patient's Ethnicity,
- Patient's Method of Payment,
- Date of Patient Entry,
- Registering Group Code (all studies with Group participation),
- Registering Institution Code (mandatory as of April 1999), and

- PATIENT_RACES Table.

See Section 2.2.1 for descriptions of the patient demographic data elements.

1.3.2. COMPLETE CDUS DATA SET

The Complete CDUS Data Set contains the information found in the Abbreviated CDUS Data Set, patient administrative information (e.g., registering institution code, patient treatment status), treatment information (e.g., agent administered, total dose per course), Adverse Event information (e.g., AE type, grade), and response information (e.g., response observed, date response observed). In short, the Complete CDUS Data Set includes all data elements described in Section 2 of this document.

Note: Data related to Phase 1 end points are only required to be submitted for Phase 1 trials for the recommended Phase 2 dose or the minimum effective dose, depending on protocol objectives.

The complete report should be submitted quarterly (Cooperative Groups may submit Phase 2 response data within 6 weeks of the completion of each stage of the study. Response data for all Phase 1 trials and non-Group Phase 2 trials should be submitted quarterly).

1.3.3. TRIAL CATEGORIES

The following sections describe the various trial “categories” and the amount of information necessary for each¹. A summary of this information can be found in Table A and Table B. A description of each data element to be collected can be found in Section 2.

1.3.3.1. Treatment Trials that include DCTD-Supplied Investigational Agents

Cooperative Group and Research Base trials and non-Cooperative Group (Cancer Center or other institution) trials:

1.3.3.1.1. PHASE 1 – CTMS MONITORED TRIALS THAT INCLUDE DCTD-SUPPLIED INVESTIGATIONAL AGENTS

Early Phase 1 trials often require more intensive monitoring. Early Phase 1 trials will continue to be reported to CTEP using the Clinical Trials Monitoring Service (CTMS). CTEP will abstract the CDUS information subset from the CTMS data on a monthly basis. Investigators will not be obligated to submit any additional data to the CDUS.

¹ Please note that the NCI may choose to “upgrade” a Phase 1 or 2 treatment study from abbreviated to complete CDUS reporting based on the priority of the trial. Investigators will be notified in writing during the consensus review and protocol approval process regarding the reporting requirements for a given study.

1.3.3.1.2. PHASE 1 – NON-CTMS MONITORED TRIALS THAT INCLUDE DCTD-SUPPLIED INVESTIGATIONAL AGENTS

A Complete CDUS Data Set report (all CDUS data elements) is required. Investigators should submit the Complete CDUS Data Set report to CTEP on a quarterly basis.

1.3.3.1.3. PHASE 2 TRIALS THAT INCLUDE DCTD-SUPPLIED INVESTIGATIONAL AGENTS

A Complete CDUS Data Set report is required (all CDUS data elements except Phase 1 endpoints). Investigators should submit the Complete CDUS Data Set report to CTEP on a quarterly basis. Response data for all non-Cooperative Group Phase 2 trials should be submitted quarterly. Response data for Cooperative Group Phase 2 trials may be submitted within 6 weeks of the completion of each stage of the study.

1.3.3.1.4. PHASE 3 TRIALS THAT INCLUDE DCTD-SUPPLIED INVESTIGATIONAL AGENTS

An Abbreviated CDUS Data Set report is required. Investigators should submit the Abbreviated CDUS Data Set report to CTEP on a quarterly basis for all DCTD sponsored Phase 3 treatment trials.

1.3.3.2. Treatment Trials that do not include DCTD-Supplied Investigational Agents

1.3.3.2.1. COOPERATIVE GROUP AND RESEARCH BASE TRIALS

An Abbreviated CDUS Data Set report is required. Phase 1, 2, 3 - Investigators should submit an Abbreviated CDUS Data Set report to CTEP on a quarterly basis for all DCTD sponsored Cooperative Group and CCOP Research Base treatment trials that do not utilize a DCTD-supplied investigational agent (e.g., commercial agents or non-NCI IND agents). Please note that the NCI may choose to “upgrade” a Phase 1 or 2 treatment study from Abbreviated to Complete CDUS Data Set reporting, based on the priority of a trial. Investigators will be notified in writing during the consensus review and protocol approval process regarding the reporting requirements for a given study.

Note: Adverse Events should be reported as per protocol guidelines.

1.3.3.2.2. NON-GROUP (CANCER CENTER OR OTHER INSTITUTION) TRIALS

1.3.3.2.2.1. Approved NCI Grant which requires CDUS Reporting

If CDUS reporting is a Grant requirement, investigators should submit an Abbreviated CDUS Data Set report to CTEP on a quarterly basis for all DCTD funded treatment trials that do not utilize a DCTD-supplied investigational agent (commercial agents or non-NCI IND agent). Please note that the NCI may choose to “upgrade” a Phase 1 or 2 treatment study from Abbrevi-

ated to Complete CDUS Data Set reporting based on the priority of a trial. Investigators will be notified in writing during the consensus review and protocol approval process regarding the reporting requirements for a given study.

Note: Adverse events should be reported as per protocol guidelines.

1.3.3.2.2. **Non-Group** (Cancer Center or other Institution) Trials that do not include a DCTD-Supplied Investigational agent or NCI Grant CDUS reporting is not required.

1.3.3.3. Non-Treatment Trials (pharmacokinetic, cytogenetics, etc.)

1.3.3.3.1. COOPERATIVE GROUP AND CCOP RESEARCH BASE NON-TREATMENT TRIALS

For Phase 1, 2, and 3 trials an Abbreviated CDUS Data Set report is required. Investigators should submit an Abbreviated CDUS Data Set report to CTEP on a quarterly basis for all DCTD sponsored Cooperative Group and CCOP Research Base non-treatment trials with a total expected accrual of greater than 100 patients. CDUS reporting is not required if a DCTD sponsored Cooperative Group and CCOP Research Base non-treatment trial has expected accrual of less than 100 patients.

1.3.3.3.2. NON-GROUP (CANCER CENTER OR OTHER INSTITUTION) NON-TREATMENT TRIALS

For Phase 1, 2, and 3 trials, CDUS reporting is not required.

1.3.3.4. DCP Sponsored CCOP Research Base Cancer Prevention and Control Trials (chemo-prevention; bio-marker and early detection; symptom management; pain control; rehabilitation and continuing care; and quality of life)

For Phase 1, 2, and 3 trials, an Abbreviated CDUS Data Set report is required. Investigators should submit an Abbreviated CDUS Data Set report to CTEP on a quarterly basis for all DCP sponsored Cooperative Group and CCOP Research Base cancer prevention and control trials.

TABLE A: Summary of CDUS Reporting Requirements for Cooperative Groups and CCOP Research Based trials.

Study Type	DCP	DCTD Non-Treatment ²	DCTD Treatment NCI Agent ³	DCTD Treatment Non-NCI Agent ⁴
Phase 1	Abbreviated	Abbreviated	Complete	Abbreviated
Phase 2	Abbreviated	Abbreviated	Complete	Abbreviated
Phase 3	Abbreviated	Abbreviated	Abbreviated	Abbreviated

TABLE B: Summary of Reporting Requirements for Non-Cooperative Group (Cancer Centers and other Institutions) Trials Utilizing DCTD Agents or Grant Funding (if CDUS reporting is a grant requirement).

Study Type	DCP	DCTD Non-Treatment ²	DCTD Treatment NCI Agent ³	DCTD Treatment Non-NCI Agent ⁴
Phase 1	N/A	None	Complete	Abbreviated
Phase 2	N/A	None	Complete	Abbreviated
Phase 3	N/A	None	Abbreviated	Abbreviated

1.4. WHEN DATA SHOULD BE SUBMITTED

1.4.1. FREQUENCY

CDUS reports will be submitted on a quarterly basis. CDUS reports are due by Jan. 31, Apr. 30, Jul. 31 and Oct. 31. Efforts should be made to have files successfully loaded within two weeks of the due date. Each report should reflect administrative, demographic, accrual and clinical data as of the end of the preceding month (e.g., Dec. 31, Mar. 31, Jun. 30, and Sep. 30). The first CDUS submission is due the quarter after the protocol has been approved by the NCI.

1.4.2. FIRST CDUS SUBMISSION DATE

Guideline:

Date of NCI Approval Notice	First CDUS Report	Reporting Schedule (Range)
Dec. 1 to Feb. 28 (29)	Apr. 30	January through March
Mar. 1 to May 31	Jul. 31	April through June

² Abbreviated CDUS is required for DCTD Cooperative Group and Research Base Non-Treatment trials with an expected accrual of 100 or greater patients. DCTD Cooperative Group and Research Base Non-Treatment trials with expected accrual of less than 100 patients will NOT be monitored by the CDUS.

³ CTMS-monitored Phase 1 trials should continue to be reported to CTEP using the CTMS system; these trials will not require CDUS reporting.

⁴ Please note that the NCI may choose to “upgrade” a Phase 1 or 2 treatment study from abbreviated to complete CDUS reporting based on the priority of the trial. Investigators will be notified in writing during the consensus review and protocol approval process regarding the reporting requirements for a given study.

Jun. 1 to Aug. 31
Sept. 1 to Nov. 30

Oct. 31
Jan. 31

July through September
October through December

1.4.3. SUBMISSION DURATION

CDUS submissions are required for all approved NCI studies until they reach a status of 'completed' or 'administratively completed' (see Section 2.1.1.5 for a complete description of protocol statuses).

CTEP defines the term *completed* as the following: The protocol has been closed to accrual, all patients have completed therapy, and the study has met its primary objectives. A study report/publication has been submitted to CTEP. The minimal data requirements for this study report include total accrual, adverse drug experiences and study results to date. A final report/publication will be submitted to CTEP when the data have matured and been analyzed.

A CDUS submission is required if a study has been closed to accrual but the primary objectives have not been met, or if a protocol has been approved but has not been activated. Once you have submitted patient data for a protocol closed to accrual and treatment you may discontinue submitting patient data. In these circumstances, a CDUS submission including the protocol administrative requirements must still be submitted quarterly until protocol completion. The appropriate response to the question “Any additions since the last report” (see Section 2.1.1.8) should be 'No.' The final CDUS submission for a given protocol should have a status of 'completed' or 'administratively completed.' No further CDUS submissions are required after a protocol has been completed or administratively completed.

If for some reason a study has been 'completed' but the study objectives have not been met (e.g., the study closed prematurely because of poor accrual) or the final study report is not available (e.g., the study was 'completed' 10 years ago and all records have been archived) then you may 'administratively complete' the protocol.

CTEP defines the term *administratively completed* as the following: The protocol has been completed prematurely (e.g., due to poor accrual, insufficient drug supply, IND closure). The trial is closed to further accrual and all patients have completed protocol treatment. A final study report publication is not anticipated.

1.5. METHODS OF DATA SUBMISSION

All data shall be submitted electronically, using a CTEP File Transfer Protocol (FTP) site or a CDUS Web site. Paper reports will not be accepted. Each electronic file should contain cumulative data for a single protocol. Electronic files should not contain data for multiple protocols.

Please refer to Section 4, CDUS-Smart Loader File Format Instructions, for specific file format requirements.

1.5.1. CTEP FTP SITE

The FTP site ftpctep.nci.nih.gov was established by NCI to accept the submission of data files. To ensure the security and integrity of all data, an account with a username

and password will be created for each site that will be submitting CDUS data (e.g., Cooperative Groups, Cancer Centers, etc.).

Additionally, each account will be assigned to a subdirectory within the FTP site. Viewing and submission of data files will be restricted to the assigned subdirectory. Investigators will have access to the files they have submitted, until the files are removed from the site at scheduled periodic intervals.

To request any change to an existing FTP account, or to establish a new FTP account, please contact the NCI CTEP Help Desk by telephone (301) 840-8202, fax (301) 948-2242, or e-mail at ncictephelp@ctep.nci.nih.gov.

1.5.2. CDUS WEB SITE

Investigators who do not have the resources to submit data through the CTEP FTP site mechanism can access a Web-based data entry system developed for the submission of data to CTEP. This user-friendly system includes pull-down menus, field instructions, potential selections, and pre-populated fields to minimize data entry.

The NCI CTEP Help Desk will contact the investigator to establish a Web-based user account and set up the system to enable data entry after protocol approval. Internet Explorer 5.0 and higher is recommended to access this secured Web application.

Note: The CDUS Web-based application has not been tested to support MAC or Apple computers.

1.6. PROTOCOL CODE INFORMATION

The Protocol Submission Worksheet (PSW) is available to assign codes to specific parameters within a clinical study. Studies that include Subgroups, Treatment Assignments, and/or Correlative Studies require the codes described below to facilitate protocol and amendment review and approval. In addition, the codes are utilized for multiple purposes and systems including the CDUS, and the Adverse Event Expedited Reporting (AdEERS). Generally CTEP supplies the codes for Subgroups, Treatment Assignments, and/or Correlative Studies, however, the PSW is available for investigators to propose assignments, if preferred. CTEP-assigned codes are submitted to the investigator at protocol approval and also quarterly with the *List of Expected Protocols*.

The PSW can be found on the Forms page of the CTEP Home Page.

1.6.1. CORRELATIVE STUDIES

A Correlative Study Identification Code and a Correlative Study Title must be provided for any laboratory, pharmacokinetic or other correlative study embedded in a clinical trial.

The Correlative Study Identification Code is a unique identification code assigned to each correlative study and is limited to ten alphanumeric characters (e.g., P-123).

The Correlative Study Title is the title given to the study (e.g., O⁶-benzylguanine concentrations in plasma).

1.6.2. SUBGROUPS

A Subgroup Identification Code and a Subgroup Description must accompany each clinical trial where a subgroup (stratum) is used to uniformly group patients for separate analysis or treatment. Both are mandatory for studies utilizing a DCTD-supplied investigational agent.

The Subgroup Identification Code is a unique identification code assigned to each subgroup and is limited to ten alphanumeric characters (e.g., Subgroup1). Patients on studies utilizing a single subgroup are entered on the Subgroup Identification Code such as 'SubgroupA.'

A Subgroup Description is broken into two classifications. The investigator selects the most appropriate category(s) for describing the stratification or subgroup assignment.

- *Patients Stratified by Disease:* The disease(s) must be indicated for each subgroup. A comprehensive list of CTEP Disease terms is available on the CTEP Home Page.
- *Patients Stratified by Other Classification (e.g., prior therapy, age):* The patient characteristics (other than disease) used to uniformly group patients for treatment or analysis (e.g., number of prior therapies) must be described.

1.6.3. TREATMENT ASSIGNMENTS (arm/dose levels)

Please see the *Treatment Assignment Instructions and Guidelines* available from the CTEP Home Page for a full description of Treatment Assignment Codes (TAC) and Treatment Assignment Descriptions (TAD) (also see Section 2.1.2.3 for additional information).

2. DATA ELEMENT DESCRIPTIONS

The following sections provide descriptions and valid values for each data element required by CDUS. **Investigators may potentially be required to provide some of the data elements identified below.** CTEP will also abstract some of these items from the original protocol document.

2.1. GENERAL SUMMARY INFORMATION

2.1.1. ADMINISTRATIVE

2.1.1.1. NCI Protocol Number

This is the protocol number assigned to the study by the NCI. Inter-Group protocols should use the lead Group's protocol number. Local institution protocol numbers must not be used.

2.1.1.2. Protocol Title

Supplied by CTEP. Abstracted from the protocol document.

2.1.1.3. Report Dates

2.1.1.3.1. DATE REPORT SUBMITTED

Enter today's date (format: YYYYMMDD).

2.1.1.3.2. CUT-OFF DATE FOR DATA

The most recent date for which any data were used in compiling results (format: YYYYMMDD). This date should reflect the latest date for which information is known. For example, if it is known at the end of the first quarter that all data reported are complete for that quarter, then this date would be 20020331. However, if this information can only be confirmed as of one week prior to the end of the quarter, then the date provided should be 20020324.

2.1.1.3.3. REPORT DUE DATE

The first reporting due date is supplied by CTEP with the Notice of Protocol Approval. Reports are due on the last day of each quarter until the trial has a status of 'Completed' or 'Administratively Completed.' The due dates are January 31, April 30, July 31, and October 31 of each year. Efforts should be made to have files successfully loaded within two weeks of the due date.

2.1.1.3.4. PROTOCOL ACTIVATION DATE

The protocol activation date is the date the trial was opened to accrual.

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

2.1.1.4. Primary (Lead) Institution/Group Code (CTEP ID)

Provided by CTEP. The unique CTEP code for the primary, or lead, institution or Co-operative Group.

2.1.1.5. Current Trial Status

Enter the protocol's current status using the following codes:

- AP *Approved* - Trial has official CTEP approval.
- AC *Active* - Trial is open to accrual.
- TC *Temporarily Closed to Accrual* - Trial is temporarily not accruing.
- TB *Temporarily Closed to Accrual and Treatment* - Trial is temporarily not accruing and patients are not receiving therapy.
- CL *Closed to Accrual, Patients still on Treatment* - The protocol has been closed to patient accrual. Patients are still receiving therapy.
- CB *Closed to Accrual, All Patients have Completed Treatment* - The protocol has been closed to patient accrual. All patients have completed therapy, but patients are still being followed according to the primary objectives of the study. No additional investigational agents are needed for this study.
- CP *Completed* - The protocol has been closed to accrual, all patients have completed therapy, and the study has met its primary objectives. A final study report/publication has been submitted to CTEP⁵.
- AD *Administratively Completed* - The protocol has been completed prematurely (e.g., due to poor accrual, insufficient drug supply, IND closure). The trial is closed to further accrual and all patients have completed protocol treatment. A final study report is not anticipated.

Note: The code 'RE' (Reactivated) is no longer a valid option for current protocol status.

2.1.1.6. Current Trial Status Date

Provide the date that the current trial status became effective. For example, if the current status is active, and the trial became active on January 15, 2000, then 20000215 (format: YYYYMMDD) should be submitted as the current trial status date.

To assist in determining the current trial status and the current trial status date, CTEP includes this information with each site's quarterly *List of Expected Protocols*. These can be located under the column titles 'Status Code' and 'Status Date.'

⁵ Contact the CTEP Protocol and Information Office (PIO) at (301) 496-1367 or by e-mail at pio@ctep.nci.nih.gov for final study report requirements.

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

2.1.1.7. Person Completing the Report

2.1.1.7.1. NAME

The person submitting the report is required to enter their first and last name in the following format: Last Name^First Name^Middle Initial. The middle initial is an optional entry.

2.1.1.7.2. TELEPHONE NUMBER

Telephone number where the person completing the report can be reached. All phone numbers should comply with the ASTM/NAN/CCITT format. For example, (NNN)NNN-NNNN; (NNN)NNN-NNNNXNNNN if using an extension; or NNN(NNN)NNN-NNNN when using an international telephone country code.

2.1.1.7.3. FAX NUMBER (optional)

Submit a Fax number where the person completing the report can be reached. All Fax numbers should comply with the ASTM/NAN/CCITT format (see Section 2.1.1.7.2).

2.1.1.7.4. E-MAIL ADDRESS (optional)

Submit an e-mail address where the person completing the report can be reached. Use standard SMTP format.

2.1.1.8. Additions or Changes Since the Last Report (Change Code)

Does this report contain any new data (General Summary data or patient-specific data) or has any data been changed from the last report? Enter '1' (Yes) or '2' (No). If 'Yes' is entered, then submit all available data to CTEP. If 'No' is entered, then only General Summary; Administrative data is required. When submitting data on a protocol for the first time, the response should be '1' (Yes).

2.1.1.9. Principal Investigator

Provided by CTEP. Abstracted from the protocol document.

2.1.1.9.1. NAME

Principal Investigator's Name (Last Name^First Name^Middle Initial).

2.1.1.9.2. INVESTIGATOR NUMBER

Principal Investigator's NCI Investigator Number.

2.1.1.10. Grant Information

Provide to CTEP any funding or grant information using the Protocol Submission Worksheet (PSW), if applicable. See Section 1.6 for more information on the PSW.

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

2.1.1.11. Total Accrual

2.1.1.11.1. TOTAL PLANNED ACCRUAL

The total number of patients estimated to be accrued to the study based on the information provided in the original protocol.

CTEP will abstract and enter the Total Planned Accrual from the protocol document at the time of protocol approval.

2.1.1.11.2. AMENDED PLANNED ACCRUAL

The revised total number of patients estimated to be accrued to the study based on the information provided in the most recently received protocol amendment.

CTEP will abstract and enter the Amended Planned Accrual from the protocol amendment at the time of amendment approval.

2.1.1.11.3. ACTUAL ACCRUAL

A system calculation based on the actual number of patients accrued to date on the study as reported by the lead Group or lead Institution.

Actual Accrual is based on the total number of eligible patients registered on study.

2.1.1.12. Accrual Rate (patients/month)

2.1.1.12.1. PLANNED ACCRUAL RATE

The total number of patients estimated to be accrued to the study on a monthly basis based on the information provided in the original protocol.

CTEP will abstract and enter the Planned Accrual Rate from the protocol document at the time of protocol approval.

2.1.1.12.2. AMENDED ACCRUAL RATE

The revised total number of patients estimated to be accrued to the study on a monthly basis based on the information provided in the most recently received protocol amendment.

CTEP will abstract and enter the Amended Accrual Rate from the protocol amendment at the time of amendment approval.

2.1.1.12.3. ACTUAL ACCRUAL RATE

A system calculation based on the total number of patients accrued to date on the study as reported by the lead Group or lead Institution divided by the total number of months the study has the status of Active in the CTEP database.

The CDUS uses data from the Actual Accrual (see Section 2.1.1.11.3) to make this calculation.

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

2.1.1.13. Closure Date

2.1.1.13.1. PLANNED CLOSURE DATE

The estimated date the study will meet its accrual goal calculated by the Total Planned Accrual and the Planned Accrual Rate (e.g., Total Planned Accrual/Planned Accrual Rate + Activation Date = Planned Closure Date).

CTEP will abstract and enter the Planned Closure Date from the protocol document at the time of protocol approval.

2.1.1.13.2. AMENDED CLOSURE DATE

The estimated date the study will meet its accrual goal calculated by the Total Planned (or Amended Planned) Accrual and the Planned (or Amended) Accrual Rate. All calculations reflect the most recent amendment.

CTEP will abstract and enter the Amended Closure Date from the protocol amendment at the time of amendment approval.

2.1.1.13.3. PROJECTED CLOSURE DATE

A system calculation based on multiplying the Actual Accrual Rate to determine the number of additional months needed to reach the Total Planned Accrual or Amended Planned Accrual (e.g., Total Planned Accrual/Actual Accrual Rate + Activation Date = Projected Closure Date).

2.1.2. SUBGROUPS/TREATMENT ASSIGNMENTS

A subgroup (stratum) is a unique patient characteristic used to uniformly group patients for separate analysis or treatment.

A treatment assignment is a unique treatment characteristic that will be used to uniformly group patients for separate analysis or treatment (e.g., Phase 2 or 3 treatment arm and Phase 1 dose levels). Each arm or dose level should be considered a distinct treatment assignment.

Subgroup and Treatment Assignment Codes (TACs) may be submitted using the Protocol Submission Worksheet (PSW). See Section 1.6 for more information on the PSW.

2.1.2.1. Subgroup Code

Each subgroup should have a unique code for identification. The investigator may provide a code (up to 10 characters) for each subgroup with the PSW. CTEP will abstract the subgroup code(s) from the PSW. If a protocol has only one subgroup then CTEP suggests using a Subgroup code such as 'SubgroupA.'

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

2.1.2.2. Subgroup Description

2.1.2.2.1.1. Patients Stratified by Disease

The investigator will provide the disease for each subgroup with the PSW. Investigators should use CTEP Terms. Based on investigator input, CTEP will abstract the disease for each subgroup from the PSW.

2.1.2.2.1.2. Patients Stratified by Other Classification (e.g., prior therapy, age)

The investigator will provide the patient characteristics (other than disease) for each subgroup with the PSW. Based on investigator input, CTEP will abstract the patient characteristics for each subgroup from the PSW.

2.1.2.3. Treatment Assignment (arm/dose level)

Please see the Treatment Assignment Instructions and Guidelines available from the CTEP Home Page for a full description of Treatment Assignment Codes (TAC) and Treatment Assignment Descriptions (TAD).

Because the CDUS Smart Loader will only accept pre-defined TACs, a failure to provide CTEP with enough advance notification will result in rejection of the entire CDUS data set. Notification is achieved by sending a Treatment Assignment request to the Protocol and Information Office (PIO) via e-mail at pio@ctep.nci.nih.gov.

Note: Only those TACs which have been quality checked by CTEP will be considered valid value TACs by CDUS.

2.1.3. CORRELATIVE STUDIES

Correlative studies are laboratory, pharmacokinetic or other correlative studies embedded within the primary protocol. A separate entry should be made for each correlative study. Correlative study titles and codes may be provided by investigators with the Protocol Submission Worksheet (PSW). A separate correlative study should be defined for each analysis. Note: The reporting requirements for correlative study information include protocols assigned to both CDUS-Abbreviated and CDUS-Complete reporting. See Section 1.6 for more information on the PSW.

2.1.3.1. Correlative Study Identification (ID)

Each correlative study should have a unique identification code. The investigator may provide a code for each correlative study with the PSW. CTEP will abstract the correlative study code from the PSW.

2.1.3.2. Correlative Study Title (laboratory, pharmacokinetic or other correlative studies)

Correlative study(s) titles may be provided by investigators with the PSW. CTEP will abstract the correlative study title from the protocol.

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

2.1.3.3. Correlative Study Findings

Using a separate entry for each correlative study, provide the following information:

2.1.3.3.1. PATIENTS COLLECTED

The number of patients for whom samples (blood, urine, tissue, etc.) have been collected.

2.1.3.3.2. PATIENTS ANALYZED

The number of patients for whom samples (blood, urine, tissue, etc.) have been analyzed.

2.1.3.3.3. SAMPLES COLLECTED

The number of samples gathered across patients. For example, if three samples were collected for six patients on the correlative study, then 18 samples would be reported.

2.1.3.3.4. SAMPLES ANALYZED

The number of samples analyzed across patients.

2.1.3.3.5. CORRELATIVE STUDY FINDINGS OR CONCLUSIONS

If known, briefly describe any correlative study findings or conclusions (free text field-optional).

2.1.4. PHASE 1 END POINTS AND PHASE 1 END POINT DLTs

Depending on protocol objectives, the Phase 1 end points reporting includes the recommended Phase 2 dose or the minimum effective dose. This information is mandatory for Phase 1 studies assigned to complete CDUS reporting. They are not required for other studies.

2.1.4.1. Subgroup Code

Please use the appropriate code (see Section 2.1.2.1) for designating each subgroup. A separate entry should be made for each subgroup. If a protocol has only one subgroup, CTEP suggests using a Subgroup code such as 'SubgroupA.'

2.1.4.2. Recommended Phase 2 Dose or Minimum Effective Dose

If known, provide the TAC (see Section 2.1.2.3) for the recommended Phase 2 dose or minimum effective dose for each subgroup as applicable. Determination of the recommended Phase 2 dose or minimum effective dose should be based on protocol criteria.

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

2.1.4.2.1. DOSE LIMITING TOXICITY (DLT)

2.1.4.2.1.1. Subgroup

Select the appropriate code (see Section 2.1.2.1) for the subgroup this patient was entered on. CTEP suggests coding patients enrolled on a protocol with a single subgroup with a Subgroup code such as 'SubgroupA.'

2.1.4.2.1.2. Treatment Assignment

Select the appropriate code (see Section 2.1.2.3) for the patient's treatment assignment this course (e.g., Phase 2 treatment arm, Phase 1 dose levels). Patients enrolled on a protocol with a single treatment assignment should be coded with a Treatment Assignment Code such as 'TA1.'

2.1.4.2.1.3. DLT Type

If known, select the appropriate NCI Common Terminology Criteria for Adverse Events (CTCAE) (formerly known as CTC) v2.0 or v3.0 term (see CTEP Home Page for the list of CTCAE terms) for the dose limiting toxicity(s) (Adverse Event) for each subgroup as applicable. Determination of dose limiting Adverse Events should be based on protocol criteria. More than one DLT may be entered.

Note: Either CTCAE v2.0 or v3.0 will be used to identify and submit the Adverse Event(s) depending on the assignment made to the protocol by CTEP. Only values available from the CTCAE v2.0 will be accepted for protocols assigned to CTCAE v2.0 and only values available from the CTCAE v3.0 will be accepted for protocols assigned to CTCAE v3.0.

2.1.4.2.1.4. DLT (Adverse Event) Other, Specify

Using the NCI Common Terminology Criteria for Adverse Events (CTCAE) (formerly known as CTC) v2.0 or v3.0 term (see CTEP Home Page for the list of CTCAE terms), provide the specific DLT in the AE_Other_Specify field when 'Other, Specify' is selected from the AE_Type_Code field (see Section 2.2.3.9.2.3 for additional coding details and two options for submitting AE_Other_Specify).

2.1.5. GENERAL DATA SUMMARY BY SUBGROUP AND/OR TREATMENT ASSIGNMENT (TRIAL COMMENTS)

The General Data Summary by subgroup and/or treatment assignment is optional for trials assigned to complete CDUS reporting (e.g., Phase 1 and 2 trials with DCTD-SUPPLIED investigational agents), it is not required for other studies.

2.1.5.1. Subgroup/Treatment Assignment Code

Please use the appropriate code (see Sections 2.1.2.1 and 2.1.2.3) for designating each different combination of subgroup and/or treatment assignment. A separate entry should be made for each subgroup and/or treatment assignment combination.

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

2.1.5.1.1. ADVERSE EVENT/DOSE MODIFICATIONS BY SUBGROUP AND/OR TREATMENT ASSIGNMENT

If known, please provide any observations or conclusions regarding Adverse Events and dose modifications that may not be apparent from other information on this report (free text field).

2.1.5.1.2. RESPONSE BY SUBGROUP AND/OR TREATMENT ASSIGNMENT

If known, please provide any observations or conclusions regarding response that may not be apparent from other information on this report (free text field).

2.1.6. PUBLICATIONS

A publication citation must be provided if any data for this study or any associated correlative study has been published.

2.1.6.1. Publication Identification (ID)

The investigator assigns a unique code to identify the publication for CDUS purposes. A sequential number is recommended.

For each publication, provide either the National Library of Medicine citation identification (MedLine UID) or the full citation (e.g., title, author, page number, etc.).

2.1.6.1.1. CITATION IDENTIFICATION (MEDLINE UID)

Specify the National Library of Medicine (NLM) Citation Unique Identifier (MedLine UID). The MedLine UID is a unique 8-character, alphanumeric code supplied for every publication included in MedLine. Entry of the MedLine UID eliminates the requested entry of the data elements that follow (Sections 2.1.6.1.2.1 through 2.1.6.1.2.7).

OR

2.1.6.1.2. FULL CITATION

2.1.6.1.2.1. Author Order and Name

Specify whether each author is the first author, second author, etc. (e.g., 1, 2, 3, etc.) and provide the author's name in the following format: Last Name^First Name^Middle Initial, e.g., Adams^John^Q.

2.1.6.1.2.2. Title

Enter the title of the article as it appears in the publication.

2.1.6.1.2.3. Journal

Enter the name of the journal where the article appears.

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

2.1.6.1.2.4. Volume

Enter the volume number of the journal.

2.1.6.1.2.5. Year

Enter the year that the journal was published.

2.1.6.1.2.6. Publisher

Enter the name of the publisher who produced the journal.

2.1.6.1.2.7. Pages

Enter the first and last page numbers of the article.

2.2. PATIENT-SPECIFIC DATA

2.2.1. PATIENT DEMOGRAPHIC ITEMS

Per CTEP guidelines, patient data are required via CDUS submission for every patient registered on a trial regardless of monitoring method (e.g., CDUS-Complete, CDUS-Abbreviated).

2.2.1.1. Patient ID

Enter the code that uniquely identifies the patient to this protocol.

Note: All correspondence (e.g., an Adverse Drug Experience) to CTEP regarding this patient on this protocol must use this unique identifier. Please contact CTEP regarding any changes to a patient ID on this trial (e.g., patient transfer to a new institution/Group).

2.2.1.2. Patient's Zip Code

U.S. residents - Enter the patient's home five-digit Zip code, for example 12345. The Zip code should not be submitted for patients who are not U.S. residents. The last four digits of the complete nine-digit Zip code should not be submitted to assure patient confidentiality. The code '00000' should be submitted if the Zip code is unknown.

2.2.1.3. Patient's Country Code

For non-U.S. residents only. This should be used when patient participation from foreign countries is involved. For patients from outside the U.S., enter the foreign country code. Leave blank if the patient is a U.S. resident. CTEP is using the International Standards Organization country codes. If unsure of a foreign country code, please check the CTEP Home Page.

2.2.1.4. Patient's Birth Date

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

Enter the year and month of the patient's birth (format: YYYYMM). To assure patient confidentiality, only submit the year and month of the patient's birth, do not submit the day of birth.

2.2.1.5. Patient's Gender

Enter the appropriate code:

1 = Male

2 = Female

9 = Unknown

Notes: The use of the value 'Unknown' for a patient's gender should only be used as a final alternative.

2.2.1.6. Patient's Race and Ethnicity

All NCI-sponsored trials must comply with the race and ethnicity reporting requirements guidelines set forth by the Health and Human Services, Office of Management and Budget. The guidelines are as follows:

- The ability to classify patients under more than one racial category,
- The separation of patient race and ethnicity into two data elements,

2.2.1.6.1. ETHNICITY FLAG

Provide the patient's ethnicity using the code and descriptions below. The Ethnicity_Flag is used to identify patients with Hispanic or Latino culture or origin, defined as a person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. It does not permit a multiple response that would indicate an ethnic heritage that is both Hispanic/Latino and non-Hispanic/non-Latino.

1 = Hispanic or Latino: A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race.

2 = Non-Hispanic: A person NOT meeting the definition for Hispanic or Latino.

8 = Not Reported: Patient refused or data not available

9 = Unknown: Patient is unsure of their ethnicity

Notes: The use of the value 'Not Reported' or 'Unknown' for a patient's ethnicity should only be used as a final alternative.

Patient ethnicity data is collected through the PATIENTS table (see 4.3.5 for table information).

2.2.1.6.2. RACE CODE

Provide the patient's race using the code and descriptions below. More than one race code may be used to classify patients who are multiracial. For example, a per-

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

son of European and Chinese origins will be classified as '01' (White) and '05' (Asian).

01 = White: A person having origins in any of the original peoples of Europe, the Middle East, or North Africa.

03 = Black or African American: A person having origins in any of the black racial groups of Africa. Terms such as “Haitian” or “Negro” can be used in addition to “Black or African American.”

04 = Native Hawaiian or Other Pacific Islander: A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands.

05 = Asian: A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam.

06 = American Indian or Alaska Native: A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment.

98 = Not Reported: Patient refused or data not available

99 = Unknown: Patient is unsure of their race

Notes: The use of the value 'Not Reported' or 'Unknown' for a patient's race should only be used as a final alternative.

Patient race data is collected through the PATIENT_RACES table (see 4.3.6 for table information).

2.2.1.7. Patient's Method of Payment

Report only the patient's primary method of payment using the codes listed below:

1 = Private Insurance

2 = Medicare

3 = Medicare and Private Insurance

4 = Medicaid

5 = Medicaid and Medicare

6 = Military or Veterans Sponsored, Not Otherwise Specified (NOS)

6A = Military Sponsored (including CHAMPUS or TRICARE)

6B = Veterans Sponsored

7 = Self pay (no insurance)

8 = No means of payment (no insurance)

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

98 = Other

99 = Unknown

Note: If the patient uses two primary payment methods, one is reported through the Method_of_Payment field and the second through the TRIAL_COMMENTS table.

2.2.1.8. Date of Patient Entry

Provide the date the patient entered the study (format: YYYYMMDD). CTEP recommends using the date the patient signed the Informed Consent form.

2.2.1.9. Registering Group Code

Enter the unique CTEP Group code where the patient was originally registered on study. All trials with Group participation are requested to provide the Group Code regardless of whether the study is classified as Intergroup. For example, if the lead organization is an institution, but a Cooperative Group is a participant, CTEP requests that Registering Group information be submitted. If unsure of the CTEP Group code, please check the CTEP Home Page.

Note: The following is clarification on the use of the Clinical Trials Support Unit (CTSU) value as a Registering Group Code.

Assign to 'CTSU' if:

The patient was registered through the CTSU Data Operations Center
AND the patient was NOT accrued from a Cooperative Group institution or Investigator.

Assign to the appropriate Cooperative Group if:

The patient was accrued from a Cooperative Group institution or Investigator (regardless of whether the patient was registered through the CTSU Data Operations Center).

Assign to 'Other' if:

The patient was NOT registered through the CTSU Data Operations Center
AND the patient was NOT accrued from a Cooperative Group institution or Investigator.

For more information on the CTSU, please go to www.ctsu.org.

2.2.1.10. Registering Institution Code

Refer to the CTEP Web site for Institution names and codes or for assistance in determining the correct Registering Institution Code for patients registered outside the Lead Group on an Intergroup trial.

2.2.1.10.1. NON-COOPERATIVE GROUP STUDIES

Enter the unique CTEP institution code where the patient was originally registered on study (e.g., institution where the patient signed the Informed Consent).

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

If unsure of an institution's CTEP institution code, please refer to the institution codes listed on the CTEP Home Page. If an institution code cannot be located, please contact the NCI CTEP Help Desk. If the NCI CTEP Help Desk is not able to provide an institution code, then the 'unknown' institution code ('00000') can be used as a final alternative. The 'unknown' institution code should be used infrequently and only after consulting with the NCI CTEP Help Desk.

2.2.1.10.2. COOPERATIVE GROUP STUDIES

Enter the unique CTEP institution code where the patient was originally registered on study (e.g., institution where the patient signed the Informed Consent). For patients registered at a CCOP institution, provide either the CCOP main member institution code or the CCOP component institution code (preferred).

Please refer to the rosters available through the Clinical Trials Monitoring Branch Audit Information System (CTMB-AIS) for institution and CCOP code information. Institution codes not found in a Cooperative Group's roster can be found on CTEP Home Page. If an institution code cannot be located, please contact the NCI CTEP Help Desk. If the NCI CTEP Help Desk is not able to provide an institution code, then the 'unknown' institution code ('00000') can be used as a final alternative. The 'unknown' institution code should be used infrequently and only after consulting with the NCI CTEP Help Desk.

2.2.2. PATIENT ADMINISTRATIVE ITEMS

Patient administrative items are mandatory for trials assigned to complete CDUS reporting (e.g., Phase 1 and 2 trials with DCTD-supplied investigational agents). They are not required for other studies.

Items such as Off Treatment Reason, Last Treatment Date, Off Study Reason, and Off Study Date are mandatory when applicable. Example, if the patient were still being treated, these items would not be applicable.

2.2.2.1. Treatment Status (Treatment On Study)

Is the patient currently receiving protocol treatment on-study? Enter '1' (Yes) or '2' (No).

2.2.2.2. Off Treatment Reason

If the patient is off protocol treatment, please select the most appropriate reason the patient has discontinued the treatment:

01 = Treatment completed per protocol criteria.

02 = Disease progression, relapse during active treatment.

03 = Adverse Event/Side Effects/Complications [patient removed from treatment because of treatment side effects (either physician directed or patient choice) or because of treatment complications (e.g., infection from placement of catheter)].

04 = Death on study [patient died during active treatment].

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

Note: CTEP defines “active treatment” as any form of therapy identified in the schema of the protocol (e.g., surgery; radiation; commercial chemotherapy agents, investigational agents).

- 05 = Patient withdrawal/refusal after beginning protocol therapy [patient refused to continue protocol therapy for reasons other than side effects, Adverse Event, or complications (e.g., cost, travel)].
- 06 = Patient withdrawal/refusal prior to beginning a protocol therapy.
- 07 = Alternative therapy [patient removed from protocol therapy in order to receive an alternative therapy, in spite of not meeting criteria for progression/relapse or experiencing unacceptable Adverse Event].
- 08 = Patient off-treatment for other complicating disease.
- 10 = Lost to follow-up.
- 11 = Cytogenetic resistance [the resistance to the treatment by the tissue or tumor due to a genetic trait in the patient].
- 12 = Disease progression before active treatment. Refer to value ‘04’ (above) for the definition of “active treatment.”
- 13 = No treatment, per protocol criteria.
- 98 = Other.

2.2.2.3. Date of Last Treatment

If the patient is off protocol treatment, please provide the date of the patient’s last treatment on their last treatment course. This date is mandatory when the patient is reported as being off protocol treatment (in YYYYMMDD format).

2.2.2.4. Off Study Reason

Provide the reason the patient went off-study using the following valid values:

- 01 = Protocol-defined follow-up completed
- 02 = Patient lost to follow-up
- 03 = Patient refused follow-up
- 04 = Death
- 05 = Adverse Event/Side Effects/Complications
- 98 = Other

2.2.2.5. Off Study Date

Provide the date that the patient went off study (in YYYYMMDD format).

2.2.2.6. Subgroups

Select the appropriate code (see Section 2.1.2.1) for the subgroup this patient was entered on. Patients enrolled on a protocol with a single subgroup should be coded using a Subgroup code such as 'SubgroupA.'

2.2.2.7. Ineligibility Status

Has the patient been declared ineligible? Enter '1' (Yes), or '2' (No). Enter 'Yes' only if the patient has been declared *ineligible*.

Note: All patients registered on the study are considered eligible until determined to be ineligible.

2.2.2.8. Baseline Performance Status

Enter the patient's performance status at protocol entry. Please use the Performance Status Criteria as shown in Table C. A conversion for Karnovsky scores to Zubrod scores is provided. Please convert other performance scales (CALGB, Karnovsky, Lansky) to the most appropriate corresponding Zubrod score.

TABLE C: Performance Status Criteria

ECOG (Zubrod)		Karnofsky		Lansky ⁶	
Score	Description	Score ⁷	Description	Score ⁷	Description
0	Fully active, able to carry on all pre-disease performance without restriction.	100	Normal, no complaints, no evidence of disease.	100	Fully active, normal.
		90	Able to carry on normal activity; minor signs or symptoms of disease.	90	Minor restrictions in physically strenuous activity.
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work.	80	Normal activity with effort; some signs or symptoms of disease.	80	Active, but tires more quickly
		70	Cares for self, unable to carry on normal activity or do active work.	70	Both greater restriction of and less time spent in play activity.
2	Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.	60	Requires occasional assistance, but is able to care for most of his/her needs.	60	Up and around, but minimal active play; keeps busy with quieter activities.
		50	Requires considerable assistance and frequent medical care.	50	Gets dressed, but lies around much of the day; no active play; able to participate in all quiet play and activities.
3	Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.	40	Disabled, requires special care and assistance.	40	Mostly in bed; participates in quiet activities.
		30	Severely disabled, hospitalization indicated. Death not imminent.	30	In bed; needs assistance even for quiet play.
4	Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.	20	Very sick, hospitalization indicated. Death not imminent.	20	Often sleeping; play entirely limited to very passive activities.
		10	Moribund, fatal processes progressing rapidly.	10	No play; does not get out of bed.

2.2.2.9. Prior Therapy

2.2.2.9.1. NUMBER OF PRIOR CHEMOTHERAPY REGIMENS

If a patient has previously received a chemotherapy regimen, provide the number of single or multi-agent chemotherapy regimens received. A regimen is described as a distinctive planned collection of agent(s) and/or modalities to be utilized together during a cycle or course of therapy. The total number should include a chemotherapy regimen that was discontinued for any reason (e.g., completion of

⁶ The conversion of the Lansky to ECOG scales is intended for NCI reporting purposes only.

⁷ Karnofsky and Lansky performance scores are intended to be multiples of 10.

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

therapy, Adverse Event, or disease progression). If a prior treatment was ABVD/CHOP, it should be coded as one chemotherapy regimen.

Note: The total number of other prior therapy types (e.g., surgery) is not required.

2.2.2.9.2. PRIOR THERAPY TYPE (MEDDRA CODE)

Please indicate all prior cancer treatment the patient has received. More than one therapy may be included. Multi-modality treatments should be listed separately (e.g., mastectomy followed by tamoxifen – code as surgery and hormonal therapy). Use CTEP Terms and the codes listed in the Medical Dictionary for Medical Affairs (MedDRA) (see the CTEP Home Page for a list of therapy terms and MedDRA codes).

Anti-Retroviral Therapy: Agents administered to control the replication and/or spread of viruses (e.g., TAT therapy for HIV-1).

Antisense: Treatment with an agent that prevents or impairs the translation of the genetic message for production of a specific protein.

Bone Marrow Transplant: High dose chemotherapy combined with transplantation of bone marrow cells (e.g., allogeneic, syngeneic, autologous bone marrow or peripheral blood stem cell transplantation).

Chemotherapy Not Otherwise Specified (NOS): Non-systemic chemotherapy treatment (e.g., intra-peritoneal, intra-cavitary, intra-theal), or chemotherapy not described by Chemotherapy Single Agent Systemic or Multi-Agent Systemic.

Chemotherapy Multiple Agent Systemic: Systemic chemotherapy with a regimen containing multiple agents. A regimen is described as a distinctive collection of agent(s) and/or modalities to be utilized together during a cycle or course of therapy. All routes of administration are acceptable as long as the agent is intended for systemic therapy.

Chemotherapy Non-Cytotoxic: Prior therapy with agents that are not known to cause damage to cycling cells (e.g., endostatin, mmpi, bevacizumab).

Chemotherapy Single Agent Systemic: Systemic chemotherapy with a single agent regimen. A regimen is described as a distinctive collection of agent(s) and/or modalities to be utilized together during a cycle or course of therapy. All routes of administration are acceptable as long as the agent is intended for systemic therapy.

Gene Transfer: Treatment of human disease by gene transfer.

Hormonal Therapy: Cancer therapy, which incorporates hormonal manipulation (e.g., tamoxifen, androgen deprivation).

Immunotherapy: Biologic cancer therapy. Manipulation of the body's immune system, either directly or indirectly, with therapeutic intent, e.g., tumor vaccines, monoclonal antibodies, cytokines (interferons, interleukins, tumor necrosis factor). Do not include biologic therapy as supportive care (e.g., G-CSF for immunoprotection).

No Prior Therapy: No previous exposure to drug (NOS).

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

Oncolytic Virotherapy: Anticancer treatment with a live, replication-competent virus.

Prior Therapy Not Otherwise Specified (NOS)

Radiotherapy: Targeted ionizing radiation therapy utilizing radioactive implants or seeds.

Note: Per the v5.0 MedDRA codes, the *Radiotherapy* term combines the following therapies:

Extensive Radiation: Cancer therapy using ionizing radiation to a significant (>50%) portion of the body (e.g., craniospinal, total body irradiation, or pelvic radiation).

Limited Radiation: Cancer therapy using ionizing radiation to a limited (<50%) portion of the body.

Surgery: Surgical procedure, or operation, with therapeutic intent. Do not include diagnostic procedures (e.g., biopsy).

Therapy Not Otherwise Specified (NOS)

Vaccine: A substance or group of substances administered to induce the immune system to recognize and destroy tumors or microorganisms, which can be used for prevention, amelioration, or treatment of diseases.

The table below represents the MedDRA Codes used for Prior Therapy code assignment.

TABLE D: MedDRA Codes for Prior Therapies

CTEP Term	MedDRA Preferred Term	MedDRA v1.99 Code**	MedDRA 5.0 Code*
Anti-Retroviral Therapy	Not Available	900126	90003000
Antisense	Not Available	900120	90003002
Bone Marrow Transplant	Bone Marrow Transplant NOS	3487	10005990
Chemotherapy (NOS)	Chemotherapy (NOS)	900102	10050693
Chemotherapy multiple agents systemic	Chemotherapy multiple agents systemic	23514	10008452
Chemotherapy non-cytotoxic	Not Available	900128	90003014
Chemotherapy single agent systemic	Chemotherapy single agent systemic	23518	10008456
Gene Transfer	Gene Transfer	900114	90003004
Hormonal Therapy	Steroid Therapy NOS	23557	10042027
Immunotherapy	Not Available	900104	90003006
No prior therapy	No previous exposure to drug NOS	900100	10052052
Oncolytic Virotherapy	Not Available	900124	90003008
Prior Therapy (NOS)	Not Available	900112	90003010
Radiotherapy	Radiotherapy	900110	10037794
Surgery	Operation NOS	4058	10030858
Therapy (NOS)	Not Available	900116	90003012

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

CTEP Term	MedDRA Preferred Term	MedDRA v1.99 Code**	MedDRA 5.0 Code*
Vaccine	Prophylaxis NOS	900122	10036903

*MedDRA v5.0 codes are recommended.

** MedDRA v1.99 codes are the equivalent to the International Medical Terminology (IMT) codes used in CDUS v2.0.

2.2.2.10. Patient's Disease Code

Please indicate the patient's primary cancer diagnosis. Use CTEP Terms and MedDRA Codes. If unsure of a disease term and/or code, please check the CTEP Home Page for a list of values and MedDRA Codes.

Note: If the patient's disease includes two primary cancer diagnoses, one is reported through the Disease_Code field and the second through the TRIAL_COMMENTS table.

2.2.2.11. Response Evaluation Status

Based on the criteria specified within the protocol, determine if the patient is evaluable for a response (see Section 2.2.4 for additional information).

2.2.2.12. Baseline Abnormalities Flag

Indicate whether abnormalities were found during the patient's initial history and physical examination. Baseline abnormality information will provide CTEP with a baseline to use when analyzing treatment-related Adverse Events. The valid values for this field are '1' (Yes), '2' (No), and '9' (Unknown). Set the flag to '1' (Yes) if abnormalities were found during the patient's initial examination.

The following information must be submitted through the BASELINE_ABNORMALITIES table (see Section 4.3.10) when this flag is set to '1' (Yes).

2.2.2.12.1. BASELINE ABNORMALITY TYPE, GRADE, AND OTHER, SPECIFY

Report the Baseline Abnormality Type and Grade using the NCI Common Terminology Criteria for Adverse Events (CTCAE) (formerly known as CTC) v2.0 or v3.0. Provide the specific Adverse Event in the AE_Other_Specify field when 'Other, Specify' is selected from the AE_Type_Code field (see Section 2.2.3.9.2.3 for additional coding details and two options for submitting AE_Other_Specify).

Notes:

Baseline Abnormality is defined by CTEP as any abnormal assessment (e.g., physical finding, subjective complaint, or diagnostic test abnormality) identified as part of the routine pre-study work-up for which a CTCAE term exists.

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

Either CTCAE v2.0 or v3.0 will be used to identify and submit the Adverse Event(s) depending on the assignment made to the protocol by CTEP. Only values available from the CTCAE v2.0 will be accepted for protocols assigned to CTCAE v2.0 and only values available from the CTCAE v3.0 will be accepted for protocols assigned to CTCAE v3.0.

2.2.3. PATIENT TREATMENT BY COURSE

CTEP defines the term *course (cycle)* as the following: A series of medical treatments or procedures (e.g., drug, biologic radiation) administered over a designated period. The treatment plan may call for repeated courses (cycles) of the treatment. The start, end points, and frequency of a course (cycle) should be defined by protocol criteria. If a course (cycle) is not defined by a protocol (e.g., chronic once daily dosing of an oral medication), the patient follow-up schedule may be utilized to define the course length.

Patient Treatment by Course is mandatory for trials assigned to complete CDUS reporting (e.g., Phase 1 and 2 trials with DCTD-supplied investigational agents), and is not required for other studies.

2.2.3.1. Course Identification

Indicate the course (cycle) of treatment that is being reported on (e.g., 1, 2, 3,), using the definition of treatment course given in the protocol. Use only numeric values to define the course; non-numeric values are not accepted. The course identification is to be numbered sequentially; the CDUS Smart Loader will validate that the course information is provided in chronological order. For example, the start date for course 2 should be later than the start date for course 1.

Note: When submitting a Course_ID for crossover studies, it is recommended that a second numbering convention be used to differentiate between the two regimens. For example:

Course ID sequence for initial courses: 1, 2, 3, etc.

Course ID sequence for crossover courses: 101, 102, 103, etc.

2.2.3.2. Course Start Date

Enter the date the course (cycle) began (format: YYYYMMDD).

2.2.3.3. Treatment Assignment

Select the appropriate code (see Sections 2.1.2 and 2.1.2.3) for the patient's treatment assignment this course (e.g., Phase 2 treatment arm, Phase 1 dose levels). Patients enrolled on a protocol with a single treatment assignment should be given a Treatment Assignment code such as 'TA1.'

2.2.3.3.1. PHASE 1 STUDIES

Provide a TAC for all patients assigned to a pre-identified dose level. When a Phase 1 dose level will be added or modified per protocol defined criteria, the in-

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

investigator should submit a treatment assignment update to the Protocol and Information Office (PIO) via e-mail at pio@ctep.nci.nih.gov. See Section 2.1.2.3 for further instructions.

2.2.3.4. Treating Institution Code

2.2.3.4.1. NON-COOPERATIVE GROUP STUDIES

Enter the unique CTEP institution code where the patient was treated during the current course. If unsure of an institution's CTEP institution code, please refer to the institution codes listed on the CTEP Home Page. If an institution code cannot be located, please contact the NCI CTEP Help Desk. If the NCI CTEP Help Desk is not able to provide an institution code, then the 'unknown' institution code ('00000') can be used as a final alternative. The 'unknown' institution code should be used infrequently and only after consulting with the NCI CTEP Help Desk.

2.2.3.4.2. COOPERATIVE GROUP STUDIES

Enter the unique CTEP institution code where the patient was treated during the current course. For patients registered at a CCOP institution, provide either the CCOP main member institution code or the CCOP component institution code (preferred).

Please refer to the rosters available through the Clinical Trials Monitoring Branch Audit Database for institution and CCOP code information. Institution codes not found in a Cooperative Group's roster can be found on the CTEP Home Page. If an institution code cannot be located, please contact the NCI CTEP Help Desk. If the NCI CTEP Help Desk is not able to provide an institution code, then the 'unknown' institution code ('00000') can be used as a final alternative. The 'unknown' institution code should be used infrequently and only after consulting with the NCI CTEP Help Desk.

2.2.3.5. Patient's Height

Indicate the patient's height in centimeters. Use protocol criteria to determine if actual or ideal (post-amputation) should be used for dose calculations.

2.2.3.6. Patient's Weight

Indicate the patient's weight in kilograms. Based on protocol criteria (actual or ideal) indicate the patient's weight used for dose calculations.

2.2.3.7. Patient's Body Surface Area

Calculated by CTEP based on the patient's height (cm) and weight (kg).

2.2.3.8. Dose of the Investigational Agent Received by Patient

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

2.2.3.8.1. INVESTIGATIONAL AGENT ADMINISTERED

Use the NSC number of the DCTD-supplied investigational agent. For confirmation of the NSC number, please check the CTEP Home Page for a list of agent NSC numbers.

Note: For multi-investigational agent protocols (protocols that utilize more than one DCTD-supplied investigational agent), each agent should be listed as a separate entry.

2.2.3.8.1.1. Dose Modification (Change)

Has this patient received either a dose escalation or a de-escalation of this investigational agent during this course of therapy? Use the following codes:

1 = Yes, planned (i.e., the dose was changed according to protocol guidelines)

2 = Yes, unplanned (i.e., the dose change was not a part of protocol guidelines)

3 = No

9 = Unknown

If the patient has received a previous escalation or de-escalation of this investigational agent and there has been no further change to the dose during this course, answer no.

2.2.3.8.1.2. Total Dose of the Investigational Agent Administered per Course

Indicate the actual total dose (using numbers) the patient received during this course. Do not express the dose based on the patient's size (e.g., if the patient has a BSA of 2m², answer 500 mg, not 250mg/m²). For a multi-investigational agent protocol, please make a separate entry for each agent (using the NSC number). This information may contain up to 20 digits of which three may be used for decimal places.

2.2.3.8.1.3. Dose Units

Indicate the dosing units (e.g., mg) administered to the patient. Please see Section 6, CDUS - Valid Values, for a list of dose unit values.

2.2.3.9. Patient-Specific Adverse Event Reporting Requirements

An Adverse Event is any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medical treatment or procedure **regardless** of whether it is considered related to the medical treatment or procedure (attribution of unrelated, unlikely, possible, probable or definite).

Adverse event reporting is mandatory for all studies assigned to complete CDUS reporting (e.g., Phase 1 and 2 trials that have utilized a DCTD-supplied investigational agent).

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

A complete description of the adverse reporting requirements for investigational agents is outlined in the *NCI Guidelines: Adverse Event Reporting Requirements for NCI Investigational Agents*, available from the CTEP Home Page.

Frequency – Report quarterly. All Adverse Events must be reported by the course (cycle) in which they occurred.

Grade/Attribution Requirements – Grade 1 and 2 Adverse Events with an attribution of possible, probable, definite. All grade 3, 4, and 5 Adverse Events, regardless of attribution must be reported (see Table E).

TABLE E: Routine Adverse Event Reporting Guidelines for CDUS

Attribution	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Unrelated			CDUS	CDUS	CDUS
Unlikely			CDUS	CDUS	CDUS
Possible	CDUS	CDUS	CDUS	CDUS	CDUS
Probable	CDUS	CDUS	CDUS	CDUS	CDUS
Definite	CDUS	CDUS	CDUS	CDUS	CDUS

Note: The CDUS is not a substitute for the submission of an Adverse Event Expedited Report. All appropriate Adverse Events should also be reported as an Adverse Event Expedited Report as outlined in the *NCI Guidelines: Adverse Event Reporting Requirements for NCI Investigational Agents*.

Persistent Adverse Events – An Adverse Event that persists from one course (cycle) to another should only be reported once unless the grade becomes more severe in a subsequent course. An Adverse Event, which resolves and then recurs during a different course (cycle), must be reported each course (cycle) it recurs.

- A patient experiences Grade 3 thrombocytopenia during cycle one. During cycle two the Adverse Event persists but the severity remains unchanged. During cycle three the Adverse Event persists but increases in severity to Grade 4. The following should be reported:

Cycle One – Grade 3 Thrombocytopenia

Cycle Two – No Report

Cycle Three – Grade 4 Thrombocytopenia

Baseline Adverse Events – (See Section 2.2.2.12 for reporting Baseline Abnormalities.) An Adverse Event should NOT be reported if a patient is entered on a study with a preexisting condition (e.g., elevated laboratory value). If the Adverse Event increases in severity, the investigator should re-assess the event to determine if an Adverse Event should be reported (determine attribution). If the Adverse Event resolves and then returns, the investigator should re-assess the event to determine if the

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

event should be reported. No modification in grading should be made to account for abnormalities noted at baseline. For example:

- A patient enters a trial with an AST equivalent to Grade 1. If the AST remains unchanged at the end of cycle one, the Adverse Event should NOT be reported. If the AST increases to a Grade 3 level, the Adverse Event should be re-assessed and reported if it fulfills the other Adverse Event reporting criteria. The AST would be reported at Grade 3 with no adjustment for the baseline AST equivalent to Grade 1.
- A patient enters a study with diarrhea equivalent to Grade 2. The diarrhea resolves during the first cycle of therapy. If, during a subsequent cycle the patient experienced Grade 2 diarrhea, the Adverse Event should be re-assessed and reported if it fulfills Adverse Event reporting guidelines.

2.2.3.9.1. PATIENTS EXPERIENCING AN ADVERSE EVENT DURING THE CURRENT COURSE OF THERAPY

Use the following codes to indicate that the patient experienced an Adverse Event on the current course of therapy:

1 = Yes

2 = No

3 = Too early to evaluate

To accommodate all reporting situations, the definition of 'No' is used to indicate that the patient did not experience any Adverse Events *that are required to be reported via CDU*. For example, if during a course of treatment a patient only experienced a Grade 1 Adverse Event with an attribution of 'Unlikely,' then the AE_ Experienced flag may be reported as 'No.' The site is not required to report the event.

However, although not required by CTEP, the site does have the option to choose to report these events. If a site chooses to report these cases to CTEP, then the AE_ Experienced flag should be reported as 'Yes.'

2.2.3.9.2. PATIENTS EXPERIENCING AN ADVERSE EVENT

Indicate the following information for patients who experience an Adverse Event.

2.2.3.9.2.1. Adverse Event Type

Using the NCI Common Terminology Criteria for Adverse Events (CTCAE) (formerly known as CTC) v2.0 or v3.0, select the appropriate term (see the CTEP Home Page for a list of CTCAE terms) for the Adverse Event the patient experienced during this treatment course. More than one Adverse Event may be entered.

Note: Either CTCAE v2.0 or v3.0 will be used to identify and submit the Adverse Event(s) depending on the assignment made to the protocol by CTEP. Only values available from the CTCAE v2.0 will be accepted for protocols

assigned to CTCAE v2.0 and only values available from the CTCAE v3.0 will be accepted for protocols assigned to CTCAE v3.0.

2.2.3.9.2.2. Grade

Grade represents the severity of the Adverse Event.

Using the NCI Common Terminology Criteria for Adverse Events (CTCAE) (formerly known as CTC) v2.0 or v3.0, enter the highest grade for each Adverse Event experienced. Only the highest-grade of each Adverse Event type should be reported during a given course. For example, if a patient experiences a grade 1, grade 2, and grade 3 Adverse Event of Adverse Event Type “X” during the same course, you would report just the grade 3 Adverse Event. However, if this same patient experiences a grade 4 Adverse Event of Adverse Event Type “X” during a later course of treatment, you would submit both the grade 3 and the grade 4 as they occurred in different courses.

General definitions of the grading scale include:

- 1 - Mild Adverse Event
- 2 - Moderate Adverse Event
- 3 - Severe Adverse Event
- 4 - Life-threatening or disabling Adverse Event
- 5 - Fatal Adverse Event

2.2.3.9.2.3. Adverse Event – Other, Specify

Each category of the NCI Common Terminology Criteria for Adverse Events (CTCAE) (formerly known as CTC) v2.0 and v3.0 provides an 'Other, Specify' option for Adverse Events that are not listed in the available Adverse Event criteria (e.g., Gastrointestinal: Other, Specify; Blood/Bone Marrow: Other, Specify; etc.). Provide the specific Adverse Event in the AE_Other_Specify field when 'Other, Specify' is selected from the AE_Type_Code field. For example, Hyperkeratosis is not a CTCAE term but is a very specific dermatologic manifestation associated with the use of a specific class of new agents. In this case, 'DERMATOLOGY/SKIN, Other, Specify' is selected and Hyperkeratosis is entered as the actual Adverse Event term. All categories of the CTCAE allow for such specificity when the appropriate term is not included in the CTCAE.

Note: For the same Protocol_ID, Patient_ID, Course_ID, AE_Type_Code, and AE_Grade_Code, if more than one Adverse Event is being designated using AE_Other_Specify, the events must now be designated together using the free text field. Submitting the events separately will generate a Duplicate Primary Key (R0017) error.

For example:

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

Option 1

"ADVERSE_EVENTS","9999","101-88",3,90004068,2,"infection, right oral cavity",1,"9"

"ADVERSE_EVENTS","9999","101-88",3,90004068,2,"right face/neck swelling",1,"9"

The AE_Other_Specify data, presented in Option 1 above, should be submitted as one record, as shown in Option 2, below.

Option 2

ADVERSE_EVENTS","9999","101-88",3,90004068,2,"infection, right oral cavity; right face/neck swelling",1,"9"

Note: To adjust for this limitation (effective October 1, 2003), AE_Other_Specify will become part of the Primary Key. This provides the option to either update submissions (Option 2) or to submit the items in separate records (Option 1) without generating a duplicate Primary Key error.

2.2.3.9.2.4. Attribution

Attribution is the determination of whether an Adverse Event is related to a medical treatment or procedure.

Assess the relationship between the Adverse Event and the investigational agent, then from the list below, assign the appropriate category of attribution. Attribution must be assigned to all reported Adverse Events.

TABLE F: Attribution of Adverse Events

Code	Descriptor	Definition
1	Unrelated	The Adverse Event is <i>clearly not related</i> to the investigational agent(s)
2	Unlikely	The Adverse Event is <i>doubtfully related</i> to the investigational agent(s)
3	Possible	The Adverse Event <i>may be related</i> to the investigational agent(s)
4	Probable	The Adverse Event is <i>likely related</i> to the investigational agent(s)
5	Definite	The Adverse Event is <i>clearly related</i> to the investigational agent(s)

2.2.3.9.2.5. Adverse Event Expedited Report

Using the codes below, indicate whether an Adverse Event expedited (Ad-EERS) report was submitted to CTEP for this specific Adverse Event.

1 = Yes

2 = No

9 = Unknown

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

2.2.3.9.3. LATE ADVERSE EVENT

Provide the following information when an Adverse Event is observed after a patient has completed treatment regardless of whether the event has been identified as part of a scheduled or unscheduled follow-up.

Note: Because these Adverse Events are not associated with a particular treatment course, they cannot be collected through the ADVERSE_EVENTS table, which is linked to the TREATMENT_COURSES table. Under these circumstances, the Adverse Event is reported using the LATE_ADVERSE_EVENTS table (see Section 4.3.12 for table information).

2.2.3.9.3.1. Late Adverse Event Type, Grade, and Other, Specify

Report the Late Adverse Event Type and Grade using the NCI Common Terminology Criteria for Adverse Events (CTCAE) (formerly known as CTC) v2.0 or v3.0. Provide the specific Adverse Event in the AE_Other_Specify field when 'Other, Specify' is selected from the AE_Type_Code field (see Section 2.2.3.9.2.3 for additional coding details and two options for submitting AE_Other_Specify).

Note: Either CTCAE v2.0 or v3.0 will be used to identify and submit the Adverse Event(s) depending on the assignment made to the protocol by CTEP. Only values available from the CTCAE v2.0 will be accepted for protocols assigned to CTCAE v2.0 and only values available from the CTCAE v3.0 will be accepted for protocols assigned to CTCAE v3.0.

2.2.3.9.3.2. Attribution

Provide the determination of whether the Late Adverse Event is related to a medical treatment or procedure (see Section 2.2.3.9.2.4 for details).

2.2.3.9.3.3. Late Adverse Event Start Date

The Adverse Event Start Date is the date when a laboratory value, imaging, or other diagnostic measurement identifies the onset of an Adverse Event.

2.2.4. RESPONSE OF PATIENT'S MALIGNANCY

Requested for trials assigned to Complete CDUS reporting, e.g., Phase 1 and 2 trials with DCTD-supplied investigational agents⁸. It is not required for other studies.

2.2.4.1. Evaluable for Response

Based on the protocol criteria, indicate whether the patient is evaluable for response. Use the following codes:

⁸ Response data for all Phase 1 trials and all non-Cooperative Group Phase 2 trials should be submitted quarterly. Response data for Cooperative Group and CCOP Research Base Phase 2 trials may be submitted within six weeks of the completion of each stage of the study.

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.

1 = Yes

2 = No

3 = Too Early

7 = Not applicable (e.g., response is not a protocol end point).

2.2.4.1.1. RESPONSE (CATEGORY)

If the patient is evaluable for response, indicate the patient's response. All responses must be confirmed by protocol criteria before being reported. Use the following codes to identify each Response Category:

01 = Complete response

02 = Partial response

03 = Less than partial response (including categories of minor response and mixed response)

04 = Stable

Note: Stable disease is reported using the date the test or procedure was performed indicating that the patient had stable disease.

05 = Progression

Note: Applicable to disease progression after a response (i.e., PR or CR), after stable disease, or as initial response to protocol therapy.

06 = Not assessed adequately

98 = Other

Notes:

Progression should be reported even if it is experienced after a response (e.g., Less than partial response, Partial response, Complete response).

Protocols that do not use the traditional response criteria provided in the list of values (e.g., where the response is based on serum level changes of a particular factor) may submit the value of 'Other' to indicate a patient's response. If 'Other' is submitted, it is mandatory that information about the patient's response be submitted through the General Response Comments (see Sections 2.1.5.1.2 and 4.3.14 for further information).

2.2.4.1.2. RESPONSE (OBSERVED DATE)

The Observed Date is mandatory for all responses submitted via CDUS-Complete, including Stable Disease or Progression. The Observed Date for each level of response is the initial date that the patient's disease was shown to have responded to therapy sufficient to meet the protocol-specified criteria for that level of response.

Note: Investigators may potentially be required to provide data elements described in Section 2. A description of the data sets required for submission is found in Section 1.3.

CTEP Home Page: <http://ctep.cancer.gov/>

June 10, 2003

Produced by CTIS, Inc.


Note that the response should be confirmed as per protocol guidelines prior to reporting via CDUS (see Section 2.2.4.1.1).

The Observed Date format is YYYYMMDD.

3. CDUS - DATA MODEL

The CDUS Data Model is depicted in Figure 1. This model is provided to assist in understanding the relationships among the CDUS data elements. The model can also be used as a reference for enhancing existing systems or in the development of new systems if desired.

FIGURE 1: The CDUS Data Model diagram



4. CDUS - SMART LOADER FILE FORMAT INSTRUCTIONS

4.1. INTRODUCTION

The CDUS Smart Loader is designed to populate the database from a single text file that is electronically submitted to CTEP. The general format of a Smart Loader file is as follows:

CTEP recommends use of the following file naming convention: NCI Protocol Number_date (format: YYYYMMDD). For example, T95-0036_19980430.

Each text file will contain information for one Protocol only.

Each record associated with a Table in the database will occupy a single line.

Each record will be preceded by the Table Name it belongs to.

Each field in the record will be comma (,) delimited.

All the Varchar2 data types will be enclosed within double quotes (" ").

All dates⁹ must be in YYYYMMDD format. Partial dates should not be submitted.

If a field is left null in record, a comma should still be submitted for that field.

4.2. RELATION BETWEEN ENTITIES

One Protocol can have one or many Collections associated with it (one collection per quarter for every Protocol).

One Protocol can have one or many Correlative Studies associated with it.

One Protocol can have one or many Publications associated with it.

Every Publication can have one or many Authors.

One Protocol can have one or many Patients associated with it.

One Protocol can have one or many Summaries (Adverse Event/Response) associated with it.

Every Patient can have one or more races.

Every Patient can have under gone multiple Prior Therapies.

Every Patient can exhibit multiple Best Responses, one per each Best Response Category entered.

Every Patient can undergo one or many Treatment Courses.

Each Treatment course can be comprised of one or many Course Agents.

There can be one or many Adverse Events for every Treatment Course for a Patient.

There can be one or many Adverse Events specified for every 'AE_Other_Specify.'

⁹ With the exception of patient's date of birth which must be submitted in YYYYMM format.

There can be multiple Phase 1-End-Points for every Subgroup.

There can be multiple DLTs for every Subgroup.

4.3. FILE FORMAT

Data should be submitted for each of the following tables:

COLLECTIONS
CORRELATIVE_STUDIES
PUBLICATIONS
AUTHORS
PATIENTS
PATIENT_RACES
PRIOR_THERAPIES
TREATMENT_COURSES
COURSE_AGENTS
BASELINE_ABNORMALITIES
ADVERSE_EVENTS
LATE_ADVERSE_EVENTS
BEST_RESPONSES
TRIAL_COMMENTS
PHASE1_END_POINTS
PHASE1_END_POINT_DLTS

A list of the data items contained in each table is presented in the following sections. The format for the data items contained in each table is also presented. For an example of how each record should appear when containing actual data, please see Section 5, CDUS Smart Loader Sample File.

Note: Italicized items represent Primary Keys for the respective tables.

4.3.1. COLLECTIONS TABLE

Each record associated with the COLLECTIONS Table should consist of the following information:

<i>Protocol_ID</i>	<i>Varchar2(35)</i>
<i>Subm_Date</i>	<i>Date (YYYYMMDD)</i>
<i>CutOff_Date</i>	<i>Date (YYYYMMDD)</i>

Current_Trial_Status_Code	Varchar2(2)
Current_Trial_Status_Date	Date (YYYYMMDD)
Completer_Name ¹⁰	Varchar2(87)
Completer_Phone	Varchar2(20)
Completer_FAX	Varchar2(20)
Completer_Email	Varchar2(50)
Change_Code	Varchar2(1)

A sample record associated with the COLLECTIONS Table will appear as follows:

"COLLECTIONS","<Protocol_ID>",<Subm_Date>,<CutOff_Date>,<Current_Trial_Status_Code>",<Current_Trial_Status_Date>",<Completer_Name>",<Completer_Phone>",<Completer_FAX>",<Completer_Email>",<Change_Code>"

4.3.2. CORRELATIVE_STUDIES TABLE

Each record associated with the CORRELATIVE_STUDIES Table should consist of the following information:

<i>Protocol_ID</i>	<i>Varchar2(35)</i>
<i>Correlative_Study_ID</i>	<i>Varchar2(10)</i>
Patients_Collected	Number(6)
Patients_Analyzed	Number(6)
Samples_Collected	Number(6)
Samples_Analyzed	Number(6)
Findings	Varchar2(2000)

A sample record associated with the CORRELATIVE_STUDIES Table will appear as follows:

"CORRELATIVE_STUDIES","<Protocol_ID>",<Correlative_Study_ID>,<Patients_Collected>,<Patients_Analyzed>,<Samples_Collected>,<Samples_Analyzed>,<Findings>"

4.3.3. PUBLICATIONS TABLE

Each record associated with the PUBLICATIONS Table should consist of the following information:

<i>Protocol_ID</i>	<i>Varchar2(35)</i>
<i>Publication_ID</i>	<i>Number(6)</i>
Medline_UID	Varchar2(8)
Title	Varchar2(2000)

¹⁰ Completer_Name should be submitted in the format Last name^First name^Middle initial, e.g., Public^John^Q. This information will be converted internally by CTEP during the Smart Loader data load into the three separate fields depicted on the data model.

Journal	Varchar2(200)
Volume	Varchar2(50)
Year	Number(4)
Publisher	Varchar2(50)
Pages	Varchar2(50)

A sample record associated with the PUBLICATIONS Table will appear as follows:

"PUBLICATIONS","<Protocol_ID>",<Publication_ID>",<Medline_UID>",<Title>","<Journal>",<Volume>",<Year>",<Publisher>",<Pages>"

4.3.4. AUTHORS TABLE

Each record associated with the AUTHORS Table should consist of the following information:

<i>Protocol_ID</i>	<i>Varchar2(35)</i>
<i>Publication_ID</i>	<i>Number(6)</i>
<i>Author_Order</i>	<i>Number(3)</i>
Author_Name ¹¹	Varchar2(87)

A sample record associated with the AUTHORS Table will appear as follows:

"AUTHORS","<Protocol_ID>",<Publication_ID>,<Author_Order>",<Author_Name>"

4.3.5. PATIENTS TABLE

Each record associated with the PATIENTS Table should consist of the following information:

<i>Protocol_ID</i>	<i>Varchar2(35)</i>
<i>Patient_ID</i>	<i>Varchar2(20)</i>
Zip_Code	Varchar2(10)
Country_Code	Varchar2(2)
Birth_Date	Date (YYYYMM)
Gender_Code	Varchar2(1)
Ethnicity_Flag	Varchar2(1)
Method_Of_Payment	Varchar2(2)
Date_Of_Entry	Date (YYYYMMDD)
Reg_Group_ID	Varchar2(6)
Reg_Inst_ID	Varchar2(6)

¹¹ Author_Name should be submitted in the format Last name^First name^Middle initial, e.g., Public^John^Q. This information will be converted internally by CTEP during the Smart Loader data load into the three separate fields depicted on the data model.

TX_On_Study	Varchar2(1)
Off_TX_Reason	Varchar2(2)
Last_TX_Date	Date (YYYYMMDD)
Off_Study_Reason	Varchar2(2)
Off_Study_Date	Date (YYYYMMDD)
Subgroup_Code	Varchar2(10)
Ineligibility_Status	Varchar2(1)
Baseline_PS_Code	Varchar2(1)
Prior_Chemo_Regs	Number(2)
Disease_Code	Number(10)
Resp_Eval_Status	Varchar2(1)
Baseline_Abnormalities_Flag	Varchar2(1)

A sample record associated with the PATIENTS Table will appear as follows:

"PATIENTS","<Protocol_ID>","<Patient_ID>","<Zip_Code>","<Country_Code>","<Birth_Date>","<Gender_Code>","<Ethnicity_Flag>","<Method_Of_Payment>","<Date_Of_Entry>","<Reg_Group_ID>","<Reg_Inst_ID>","<TX_On_Study>","<Off_TX_Reason>","<Last_TX_Date>","<Off_Study_Reason>","<Off_Study_Date>","<Subgroup_Code>","<Ineligibility_Status>","<Baseline_PS_Code>","<Prior_Chemo_Regs>","<Disease_Code>","<Resp_Eval_Status>","<Baseline_Abnormalities_Flag>"

4.3.6. PATIENT_RACES TABLE

Each record associated with the PATIENT_RACES table should consist of the following information:

<i>Protocol_ID</i>	<i>Varchar2(35)</i>
<i>Patient_ID</i>	<i>Varchar2(20)</i>
<i>Race_Code</i>	<i>Varchar2(2)</i>

A sample record associated with the PATIENT_RACES table will appear as follows:

"PATIENT_RACES","<Protocol_ID>","<Patient_ID>","<Race_Code>"

4.3.7. PRIOR_THERAPIES TABLE

Each record associated with the PRIOR_THERAPIES Table should consist of the following information:

<i>Protocol_ID</i>	<i>Varchar2(35)</i>
<i>Patient_ID</i>	<i>Varchar2(20)</i>
<i>Therapy_Code</i>	<i>Number(10)</i>

A sample record associated with the PRIOR_THERAPIES Table will appear as follows:

"PRIOR_THERAPIES","<Protocol_ID>","<Patient_ID>",<Therapy_Code>

4.3.8. TREATMENT_COURSES TABLE

Each record associated with the TREATMENT_COURSES Table should consist of the following information:

<i>Protocol_ID</i>	<i>Varchar2(35)</i>
<i>Patient_ID</i>	<i>Varchar2(20)</i>
<i>Course_ID</i>	<i>Number(6)</i>
Course_Start_Date	Date (YYYYMMDD)
TX_Asgmnt_Code	Varchar2(10)
Treating_Inst_ID	Varchar2(6)
Height	Number(6,1)
Weight	Number(6,1)
AE_Experienced	Varchar2(1)

A sample record associated with the TREATMENT_COURSES Table will appear as follows:

"TREATMENT_COURSES","<Protocol_ID>","<Patient_ID>",<Course_ID>,<Course_Start_Date>,"<TX_Asgmnt_Code>","<Treating_Inst_ID>",<Height>,<Weight>,"<AE_Experienced>"

4.3.9. COURSE_AGENTS TABLE

Each record associated with the COURSE_AGENTS Table should consist of the following information:

<i>Protocol_ID</i>	<i>Varchar2(35)</i>
<i>Patient_ID</i>	<i>Varchar2(20)</i>
<i>Course_ID</i>	<i>Number(6)</i>
<i>Agent_ID</i>	<i>Varchar2(8)</i>
Dose_Change	Varchar2(1)
Dose_Amount	Number(20,3)
Unit_Code	Varchar2(12)

A sample record associated with the COURSE_AGENTS Table will appear as follows:

"COURSE_AGENTS","<Protocol_ID>","<Patient_ID>",<Course_ID>,"<Agent_ID>","<Dose_Change>",<Dose_Amount>,"<Unit_Code>"

4.3.10. BASELINE_ABNORMALITIES TABLE

Each record associated with the BASELINE_ABNORMALITIES table should consist of the following information:

<i>Protocol_ID</i>	<i>Varchar2(35)</i>
<i>Patient_ID</i>	<i>Varchar2(20)</i>
<i>AE_Type_Code</i>	<i>Number(10)</i>
<i>AE_Grade_Code</i>	<i>Number(1)</i>
<i>AE_Other_Specify</i>	<i>Varchar2(100)</i>

A sample record associated with the BASELINE_ABNORMALITIES table will appear as follows:

"BASELINE_ABNORMALITIES","<Protocol_ID>","<Patient_ID>",<AE_Type_Code>,<AE_Grade_Code>,"<AE_Other_Specify>"

4.3.11. ADVERSE_EVENTS TABLE

Each record associated with the ADVERSE_EVENTS Table should consist of the following information:

<i>Protocol_ID</i>	<i>Varchar2(35)</i>
<i>Patient_ID</i>	<i>Varchar2(20)</i>
<i>Course_ID</i>	<i>Number(6)</i>
<i>AE_Type_Code</i>	<i>Number(10)</i>
<i>AE_Grade_Code</i>	<i>Number(1)</i>
<i>AE_Other_Specify</i>	<i>Varchar2(100)</i>
<i>AE_Attribution_Code</i>	<i>Number(1)</i>
<i>AER_Filed</i>	<i>Varchar2(1)</i>

A sample record associated with the ADVERSE_EVENTS Table will appear as follows:

"ADVERSE_EVENTS","<Protocol_ID>","<Patient_ID>",<Course_ID>,<AE_Type_Code>,<AE_Grade_Code>,"<AE_Other_Specify>",<AE_Attribution_Code>,"<AER_Filed>"

4.3.12. LATE_ADVERSE_EVENTS TABLE

Each record associated with the LATE_ADVERSE_EVENTS table should consist of the following information:

<i>Protocol_ID</i>	<i>Varchar2(35)</i>
<i>Patient_ID</i>	<i>Varchar2(20)</i>
<i>AE_Type_Code</i>	<i>Number(10)</i>

<i>AE_Grade_Code</i>	<i>Number(1)</i>
<i>AE_Other_Specify</i>	<i>Varchar2(100)</i>
<i>AE_Attribution_Code</i>	<i>Number(1)</i>
<i>AE_Start_Date</i>	<i>Date (YYYYMMDD)</i>

A sample record associated with the LATE_ADVERSE_EVENTS table will appear as follows:

"LATE_ADVERSE_EVENTS", "<Protocol_ID>", "<Patient_ID>", "<AE_Type_Code>", "<AE_Grade_Code>", "<AE_Other_Specify>", "<AE_Attribution_Code>", "<AE_Start_Date>"

4.3.13. BEST_RESPONSES TABLE

Each record associated with the BEST_RESPONSES Table should consist of the following information:

<i>Protocol_ID</i>	<i>Varchar2(35)</i>
<i>Patient_ID</i>	<i>Varchar2(20)</i>
<i>Category</i>	<i>Varchar2(2)</i>
<i>Observed_Date</i>	<i>Date (YYYYMMDD)</i>

A sample record associated with the BEST_RESPONSES Table will appear as follows:

"BEST_RESPONSES", "<Protocol_ID>", "<Patient_ID>", "<Category>", "<Observed_Date>"

4.3.14. TRIAL_COMMENTS TABLE

Each record associated with the TRIAL_COMMENTS Table (Summary information by subgroup and/or treatment assignment) should consist of the following information:

<i>Protocol_ID</i>	<i>Varchar2(35)</i>
<i>Subgroup_Code</i>	<i>Varchar2(10)</i>
<i>TX_Asgnmt_Code</i>	<i>Varchar2(10)</i>
<i>Gen_AE_Comments</i>	<i>Varchar2(2000)</i>
<i>Gen_Response_Comments</i>	<i>Varchar2(2000)</i>

A sample record associated with the TRIAL_COMMENTS table will appear as follows:

"TRIAL_COMMENTS", "<Protocol_ID>", "<Subgroup_Code>", "<TX_Asgnmt_Code>", "<Gen_AE_Comments>", "<Gen_Response_Comments>"

4.3.15. PHASE1_END_POINTS TABLE

Each record associated with the PHASE1_END_POINTS Table should consist of the following information:

<i>Protocol_ID</i>	<i>Varchar2(35)</i>
<i>Subgroup_Code</i>	<i>Varchar2(10)</i>
<i>TX_Asgnmt_Code</i>	<i>Varchar2(10)</i>

A sample record associated with the PHASE1_END_POINTS Table will appear as follows:

"PHASE1_END_POINTS", "<Protocol_ID>", "<Subgroup_Code>", "<TX_Asgnmt_Code>"

4.3.16. PHASE1_END_POINT_DLTS TABLE

Information about Phase 1 End Point Dose Limiting Toxicity is presented in this table. Each record associated with the PHASE1_END_POINT_DLTS Table should consist of the following information:

<i>Protocol_ID</i>	<i>Varchar2(35)</i>
<i>Subgroup_Code</i>	<i>Varchar2(10)</i>
<i>TX_Asgnmt_Code</i>	<i>Varchar2(10)</i>
<i>AE_Type_Code</i>	<i>Number(10)</i>
<i>AE_Other_Specify</i>	<i>Varchar2(100)</i>

A sample record associated with the PHASE1_END_POINT_DLTS Table will appear as follows:

"PHASE1_END_POINT_DLTS", "<Protocol_ID>", "<Subgroup_Code>", "<TX_Asgnmt_Code>", "<AE_Type_Code>", "<AE_Other_Specify>"

5. CDUS SMART LOADER SAMPLE FILE

"COLLECTIONS","T95-0036",19970110,19961231,"AC",19961015,"Public^John^Q","(301)111-1212","(301)111-2323","public@med.com","1"
"CORRELATIVE_STUDIES","T95-0036","950036PK",40,40,80,70,"Study Findings"
"CORRELATIVE_STUDIES","T95-0036","950036QOL",40,35,70,60,"Study Findings"
"PUBLICATIONS","T95-0036",1,"","Effectiveness of Taxol plus Cisplatin","Journal of the American Medical Association","50",1997,"McGraw Hill","10-20"
"PUBLICATIONS","T95-0036",2,"99061487","","","","",""
"AUTHORS","T95-0036",1,1,"CAREY^ROBERT^D"
"AUTHORS","T95-0036",1,2,"SMITH^JAMIE^M"
"PATIENTS","T95-0036","A5001","20595","",194206,"1","9","1",19961015,"NSABP","MD005","1","",,"","SUBGROUP1","2","1",2,12345,"1","9"
"PATIENTS","T95-0036","A5002","20595","",193608,"2","1","2",19961018,"NSABP","MD005","2","02",19961105,"04",19980819,"SUBGROUP1","2","2",2,12345,"1","1"
"PATIENTS","T95-0036","A5003","20595","",194010,"1","2","3",19961018,"NSABP","MD005","1","",,"","SUBGROUP2","1","1",0,23456,"2","2"
"PATIENT_RACES","T95-0036","A5001","01"
"PATIENT_RACES","T95-0036","A5002","01"
"PATIENT_RACES","T95-0036","A5003","03"
"PATIENT_RACES","T95-0036","A5003","01"
"PRIOR_THERAPIES","T95-0036","A5001",44544
"PRIOR_THERAPIES","T95-0036","A5001",77677
"TREATMENT_COURSES","T95-0036","A5001",1,19961015,"A1","MD005",170.5,61.3,"2"
"TREATMENT_COURSES","T95-0036","A5001",2,19961021,"A1","MD005",170.5,61.3,"1"
"TREATMENT_COURSES","T95-0036","A5002",1,19961018,"A1","MD005",152.4,73.6,"2"
"TREATMENT_COURSES","T95-0036","A5003",1,19961018,"A1","MD005",180.3,95.4,"2"
"COURSE_AGENTS","T95-0036","A5001",1,"673089","2",258,"mg"
"COURSE_AGENTS","T95-0036","A5001",1,"119875","2",375,"mg"
"COURSE_AGENTS","T95-0036","A5001",2,"673089","2",258,"mg"
"COURSE_AGENTS","T95-0036","A5001",2,"119875","2",375,"mg"
"COURSE_AGENTS","T95-0036","A5002",1,"673089","2",245,"mg"
"COURSE_AGENTS","T95-0036","A5002",1,"119875","2",350,"mg"
"COURSE_AGENTS","T95-0036","A5003",1,"673089","2",278,"mg"
"COURSE_AGENTS","T95-0036","A5003",1,"119875","2",380,"mg"
"BASELINE_ABNORMALITIES","T95-0036","A5002",455095,3,""
"ADVERSE_EVENTS","T95-0036","A5001",2,455095,4,"",4,"1"
"LATE_ADVERSE_EVENTS","T95-0036","A5002",455095,4,"",,19980710
"BEST_RESPONSES","T95-0036","A5001","02",19961120
"BEST_RESPONSES","T95-0036","A5002","05",19960530
"BEST_RESPONSES","T95-0036","A5003","06",19961130
"TRIAL_COMMENTS","T95-0036","SUBGROUP1","A1","","Response seen in one of two patients"
"TRIAL_COMMENTS","T95-0036","SUBGROUP2","A1","No Toxicity",""
"PHASE1_END_POINTS","T95-0036","SUBGROUP1","A1"
"PHASE1_END_POINT_DLTS","T95-0036","SUBGROUP1","A1",455095,""

6. CDUS - VALID VALUES

The following table describes the valid values used for the CDUS data elements.

TABLE G: Valid Values

Table Name	Column Name	List of Values	Description
COLLECTIONS	Current_Trial_Status_Code	AP	Approved
		AC	Active
		TC	Temporarily Closed to Accrual
		TB	Temporarily Closed to Accrual and Treatment
		CL	Closed to Accrual, Patients still on Treatment
		CB	Closed to Accrual, All Patients have Completed Treatment
		CP	Completed
		AD	Administratively Completed
	Change_Code	1	Yes
		2	No
PATIENTS	Country_Code	See CTEP Home Page	
	Gender_Code	1	Male
		2	Female
		9	Unknown
	Ethnicity_Code	1	Hispanic or Latino
		2	Non-Hispanic
		8	Not Reported
		9	Unknown
	Method of Payment	1	Private Insurance
		2	Medicare
		3	Medicare and Private Insurance
		4	Medicaid
		5	Medicaid and Medicare
		6	Military or Veterans Sponsored NOS
		6A	Military Sponsored (including CHAMPUS & TRICARE)
		6B	Veterans Sponsored
		7	Self Pay (No Insurance)
		8	No means of payment (no insurance)
		98	Other
		99	Unknown
	Reg_Group_ID	See CTEP Home Page	
	Reg_Inst_ID	See CTEP Home Page	
	TX_On_Study	1	Yes
		2	No
	Off_TX_Reason	01	Treatment completed per protocol criteria
		02	Disease progression, relapse during active treatment
		03	Adverse Event/Side Effects/Complications
		04	Death on Study

Table Name	Column Name	List of Values	Description
PATIENTS (cont.)	Off_TX_Reason (cont.)	05	Patient withdrawal/refusal after beginning protocol therapy
		06	Patient withdrawal/refusal before beginning protocol therapy
		07	Alternative therapy
		08	Patient off-treatment for other complicating disease
		10	Lost to follow-up
		11	Cytogenetic Resistance
		12	Disease Progression before Active Treatment
		13	No treatment, per protocol criteria
		98	Other
	Off_Study_Reason	01	Protocol-defined follow-up completed
		02	Patient lost to follow-up
		03	Patient refused follow-up
		04	Death
		05	Adverse Event/Side Effects/Complications
		98	Other
	Ineligibility_Status	1	Yes
		2	No
	Baseline_PS_Code	0	Normal Activity, asymptomatic
		1	Symptomatic, fully ambulatory
		2	Symptomatic; in bed < 50% of time
		3	Symptomatic; in bed > 50% of time
		4	100% bedridden
	Disease_Codes	See CTEP Home Page	(Use MedDRA Codes)
	Resp_Eval_Status	1	Yes
		2	No
		3	Too Early
		7	Not Applicable
	Baseline_Abnormalities_Flag	1	Yes
		2	No
		9	Unknown
PATIENT_RACES	Race_Code	01	White
		03	Black or African American
		04	Native Hawaiian or other Pacific Islander
		05	Asian
		06	American Indian or Alaska native
		98	Not Reported
		99	Unknown
PRIOR_THERAPIES	Therapy_Code	See CTEP Home Page	(Use MedDRA Codes)
TREATMENT_COURSES	Treating_Inst_ID	See CTEP Home Page	
	AE_Experienced	1	Yes
		2	No
COURSE_AGENTS	Dose_Change	3	Too Early to evaluate
		See CTEP Home Page	(Use NSC Numbers)
		1	Yes, planned
		2	Yes, unplanned

Table Name	Column Name	List of Values	Description
COURSE_AGENTS (cont.)	Dose_Change (cont.)	3	No
		9	Unknown
	Unit_Code	billion pfu	Billion pfu
		cells	Cells
		cm	Centimeter
		Ci	Curie
		dL	Deciliter
		dm	Decimeter
		g	Gram
		Eq	Gram-equivalent weight
		mol	Gram-molecular weight (mole)
		gravity	Gravity (in centrifugation)
		Hz	Hertz
		IU	International Unit
		Jcm2	Joules per centimeter square
		keV	Kilo-electron volt
		kg	Kilogram
		kHz	Kilohertz
		kPa	Kilopascal
		L	Liter
		MHz	Megahertz
		Mrad	Megarad
		m	Meter
		mcCi	Microcurie
		mcg	Microgram
		mcL	Microliter
		mcm	Micrometer
		mcmol	Micromole
		mCi	Millicurie
		mEq	Milliequivalent
		mg	Milligram
		million IU	Million International Units
		million pfu	Million pfu
		MMM	Milligrams per milliliter per minute
		mL	Milliliter
		mm	Millimeter
		mmol	Millimole
		MeV	Million electron volts
		MU	Million Unit
		mOsmol	Milliosmole
		milliunit	Milliunit
		mV	Millivolt
		MVP	Million Viral Particles
		nCi	Nanocurie
		ng	Nanogram
		nm	Nanometer
		nm light	Nanometers of Light
		Osmol	Osmole
		Pa	Pascal

Table Name	Column Name	List of Values	Description
COURSE_AGENTS (cont.)	Unit_Code (cont.)	percent	Percent
		pg	Picogram
		pfu	Plaque Forming Unit
		psi	Pounds per square inch
		TCID	Tissue Culture Infections Dose
		unit	Unit
		VP	Viral particles
		N/A	Not Applicable
BASELINE_ABNORMALITIES	AE_Type_Code	See CTEP Home Page	(Use MedDRA Code, see CTCAE for definition)
	AE_Grade_Code	1, 2, 3, 4, 5	(See the CTEP Home Page and CTCAE or the Interactive Web Application for definition and grade)
ADVERSE_EVENTS	AE_Type_Code	See CTEP Home Page	(Use MedDRA Code, see CTCAE for definition)
	AE_Grade_Code	1, 2, 3, 4, 5	(See the CTEP Home Page and CTCAE or the Interactive Web Application for definition and grade)
	AE_Attribution_Code	1	Unrelated
		2	Unlikely
		3	Possible
		4	Probable
		5	Definite
	AER_Filed	1	Yes
		2	No
		9	Unknown
LATE_ADVERSE_EVENTS	AE_Type_Code	See CTEP Home Page	(Use MedDRA Code, see CTCAE for definition)
	AE_Grade_Code	1, 2, 3, 4, 5	(See the CTEP Home Page and CTCAE or the Interactive Web Application for definition and grade)
	AE_Attribution_Code	1	Unrelated
		2	Unlikely
		3	Possible
		4	Probable
		5	Definite
BEST_RESPONSES	Category	01	Complete Response
		02	Partial Response
		03	Less than partial Response
		04	Stable
		05	Progression
		06	Not assessed adequately
		98	Other
PHASE1_END_POINT_DLTS	AE_Type_Code	See CTEP Home Page	(use MedDRA Code, see CTCAE for definition)

7. CDUS - SMART LOADER APPROVAL, DISAPPROVAL, AND CORRECTION PROCESS

7.1. OVERVIEW

The CTEP Smart Loader has been developed to evaluate all data submitted to the Clinical Data Update System (CDUS) for accuracy and completeness. The review process and acceptance or rejection of the data will depend on the type of error and whether a data element is considered mandatory or requested for the protocol for which data are being submitted. A listing of the business rules, including mandatory and requested data information, can be found in Section 9.

7.2. DEFINITIONS FOR MANDATORY, REQUESTED, AND OPTIONAL

The data elements have been grouped into the following categories.

7.2.1. MANDATORY DATA ELEMENTS

Mandatory data elements are those defined by CTEP as the minimum information required for processing the data submission and to track patient enrollment on a study. Investigators must submit all mandatory data elements.

7.2.2. REQUESTED DATA ELEMENTS

Requested data elements are those defined by CTEP as the minimal information necessary to fulfill the regulatory, scientific and administrative needs of the NCI. Investigators must provide all known requested data elements.

7.2.3. OPTIONAL DATA ELEMENTS

Submission of optional data is at the investigator's discretion. In general the optional fields are free text. These fields (e.g., e-mail address, correlative study findings, general data summaries by subgroup, and/or treatment assignment) should be used by investigators to provide additional data that may not be readily apparent from other information submitted.

7.3. DEFINITIONS FOR INCOMPLETE, INCORRECT, INAPPROPRIATE, AND INCONSISTENT

As described previously, the CDUS Smart Loader has been developed to review each file before it is loaded into the CDUS to help CTEP identify problems or potential problems with data submissions. The anticipated problems have been grouped into the following four categories: incorrect, incomplete, inappropriate, and inconsistent.

7.3.1. INCOMPLETE DATA

Data files that do not contain all mandatory and requested data elements will be considered incomplete.

7.3.2. INCORRECT DATA

Data that are submitted in the wrong format or with invalid codes will be considered incorrect. Please see Section 4, CDUS-Smart Loader File Format Instructions, for specific file format requirements. To determine valid values/codes, please refer to Section 6, CDUS-Valid Values.

7.3.3. INAPPROPRIATE DATA

Data that do not meet electronically preset criteria will be considered inappropriate. Examples of inappropriate submissions include values that fall outside of an expected range (e.g., patient weight > 120kg) or an incongruous date sequence (e.g., first day of treatment must be > protocol activation date). The Smart Loader will check the database for elements that have been approved in an earlier submission (e.g., Submission 1: patient weighed 150kg - data subsequently verified and approved. Submission 2: patient weighs 150kg - data accepted after review of the existing approved data in the Active Database) and will not generate an error in this case.

7.3.4. INCONSISTENT DATA

Data elements that are not expected to change from one submission to the next (e.g., patient's gender) will be considered inconsistent.

7.4. CUMULATIVE DATA

Investigators are required to send cumulative data each quarter; all data submitted from previous quarters must be submitted in subsequent quarters. Submissions may contain new data as well as updates to previously submitted data. The minimal submission requirement is data identical to that sent in the previous submission. The CDUS Smart Loader confirms the cumulative data, identifies updates within the file, and inserts the new or revised data within the record. This process is performed for every table where data are loaded. If the data are not cumulative, the file is rejected, which terminates the data load process and produces an error report.

The value of the submitted Change Code (see Section 2.1.1.8) may affect whether the cumulative data are confirmed. Submitting a Change Code of '1' (Yes, the data has changed since the last report) results in an automatic confirmation of cumulative data. The only instance where a cumulative data confirmation is not performed is when a Change Code of '2' (No, the data has not changed since the last report) AND no data for any of the tables are submitted.

Note: Submissions where no data was changed since the previous quarter (Change Code = 2) but include data other than administration items, will result in a cumulative data confirmation.

Table H: Data Submission Problem Description and Required Response¹²

Data Type	Problem Type			
	Incomplete	Incorrect	Inappropriate	Inconsistent
Mandatory Data	<ul style="list-style-type: none"> All data rejected List of missing data elements generated with <i>Rejection Notice</i> Resubmission required within 5 working days 	<ul style="list-style-type: none"> All data rejected List of errors generated with <i>Rejection Notice</i> Resubmission required within 5 working days 	<ul style="list-style-type: none"> All data rejected List of errors generated with <i>Rejection Notice</i> Resubmission required within 5 working days 	<ul style="list-style-type: none"> All data accepted List of errors generated with <i>Caution Notice</i> Verification or submission of corrected data due for next quarter's submission
Requested Data	<ul style="list-style-type: none"> Remaining data set is accepted List of missing data elements generated with <i>Caution Notice</i> Verification or submission of corrected data due for next quarter's submission 	<ul style="list-style-type: none"> All data rejected List of errors generated with <i>Rejection Notice</i> Resubmission required within 5 working days 	<ul style="list-style-type: none"> All data accepted List of errors generated with <i>Caution Notice</i> Verification or submission of corrected data due for next quarter's submission 	<ul style="list-style-type: none"> All data accepted List of errors generated with <i>Caution Notice</i> Verification or submission of corrected data due for next quarter's submission
Optional Data	N/A	N/A	N/A	<ul style="list-style-type: none"> All data accepted List of errors generated with <i>Caution Notice</i> Verification or submission of corrected data due for next quarter's submission

7.5. SUBMISSION RESULTS

7.5.1. SMART LOADER APPROVAL (SUCCESSFUL/ACCEPTED)

When a protocol data set is accepted (successfully loaded) by the Smart Loader, the investigator will receive an automatic acceptance notification by e-mail in the form of a CDUS Submission Results Notification notice. The CDUS-Successful Log Report will state "The CDU Data set for this protocol has been ACCEPTED."

7.5.2. SMART LOADER DISAPPROVAL (REJECTION)

Depending on the problems identified during the Smart Loader process, the investigator may be required to resubmit a data set, submit verification of data, or a combination of both. These errors will be identified on the CDUS – Error Log Report which is a section of the CDUS Submission Results Notification notice which is e-mailed after the file has been processed. CTEP will not make manual changes to data submitted by investigators;

¹² This table represents the general policy regarding the type of action required based on problem and data type. The actual action taken for a specific problem type may be different. Please refer to the CDUS Business Rules section for further details.

all corrections or changes to elements in a data set must be made through resubmission of the entire data set. Table H summarizes the types of problems that may be identified through the Smart Loader process, and the response required from the investigator for each. Rejection, cumulative, or caution notices will be sent to the investigator depending on the type of problem identified. A suspension notice will be sent to investigators who fail to respond to these notices within the specified time frame. A description of each notice is provided on the pages that follow.

7.6. TYPES OF ERROR NOTICES

For each submission an error log report will be generated and mailed to the submitter. The following descriptions provide details for each error category (Rejection, Caution, Cumulative).

7.6.1. CDUS REJECTION NOTICE

If a protocol data set contains incomplete, incorrect, or inappropriate mandatory data elements or incorrect requested data elements, the Smart Loader will reject the entire protocol data set, and the investigator will automatically receive a rejection notice. The rejection notice will outline the specific problems and how and when they should be corrected. Investigators will be required to resubmit their corrected data set within 5 working days. Failure to comply may result in the suspension of an investigator and/or temporary closure of the study.

The resubmitted data set must resolve all errors listed in the rejection notice before the data set can be approved.

7.6.2. CDUS CAUTION NOTICE

If a protocol data set contains inconsistent mandatory or incomplete, inappropriate or inconsistent requested or optional data elements, the Smart Loader will accept the entire data set; all problem data will be flagged for further CTEP review, and the investigator will automatically receive a caution notice. The caution notice will outline the specific problems and how and when they should be corrected or verified. Investigators will be requested to send a notice of amended data, a clarification of data, or a correction of data with the next quarterly submission of data.

7.6.2.1. Correction Process for Caution Errors

Amended Data - Data elements that are in fact correct but that have been identified as inconsistent through the Smart Loader process (e.g., a patient's gender has been corrected from a previous submission) must be noted as amended data in the CDUS Response to CTEP.

Clarified Data - Data elements that are in fact correct but have been identified as inappropriate through the Smart Loader process (e.g., a very large patient falls outside of the expected weight range) must be clarified in the CDUS Response (i.e., CTEP must be informed that the weight as reported is correct).

Corrected Data - If the Smart Loader has identified problems that are in fact mistakes and require correction of the data by the investigator, the

CDUS Response to CTEP must indicate that these elements will be corrected and returned to CTEP.

7.6.2.2. Responding to a Caution Notice

All correspondence to CTEP in response to a caution notice must be sent via e-mail and must include the following information:

- File Name,
- NCI Protocol Number,
- Name of person completing the report, and his/her phone number,
- A list of the exact fields that need to be amended from a previous submission and why (e.g., inform CTEP that a mistake was made on the patient's gender in the previous submission and the current submission is correct),
- A list of the exact fields that need to be clarified and why (e.g., inform CTEP that the weight as reported is correct), and
- A list of the exact fields that need to be corrected and will be resubmitted with the complete data set.

7.6.3. CDUS CUMULATIVE ERROR NOTICE

The minimal cumulative data submission requirement is data identical to that sent in the previous submission (see Section 7.4 for a detailed description). Once the data file is received, the cumulative data are confirmed and updates or new data are inserted within the record. The file is rejected when a discrepancy is found, this terminates the data load process and generates an error report that is sent to the submitter.

7.6.3.1. Correction and Response Process for Cumulative Errors

If the Smart Loader has identified data that you have intentionally omitted from the present quarter's submission, please identify this data via an e-mail to CTEP. CTEP will then adjust their records and re-load the file. Please list of the exact fields that need to be removed via an e-mail to CTEP.

If the Smart Loader has identified data that was inadvertently omitted, please re-submit your file with that previously omitted data included.

7.7. CDUS WARNING AND SUSPENSION LETTERS

A CDUS Warning Letter will be sent to investigators who fail to respond to a CDUS Rejection notice within the time allotted. This Warning Letter will be followed by a CDUS Suspension Letter which will be sent to investigators who fail to respond to a CDUS Warning Letter within the allotted time. This letter will state that the investigator is suspended and will not receive IND agents (ongoing patients will be continued on a case by case basis) and/or that the study has been temporary closed. The suspension notice will outline the specific problems and how they should be corrected. CTEP's Clinical Trials Monitoring Branch will be sent a copy of all suspension notices.

8. INTERPRETING THE CDUS ERROR REPORTS

The CDUS Smart Loader has been developed to evaluate all data submitted to the Clinical Data Update System (CDUS) for accuracy and completeness. The review process and acceptance or rejection of the data will depend on the type of error and whether a data element is considered mandatory or non-mandatory for the protocol for which data are being submitted. See Table H for a complete description of mandatory, requested, and optional definitions. The following section describes the Error Log Report that the system will generate for a data load via the Smart Loader.

If you have any questions or comments regarding the CDUS, please contact the NCI CTEP Help Desk by telephone at (301) 840-8202, by fax (301) 948-2242, or e-mail at ncictephhelp@ctep.nci.nih.gov. Additional information regarding the CDUS is available on the CTEP Home Page.

8.1. ERROR LOG REPORT

The CDUS Error Log Report is generated whenever a data file is uploaded via the Smart Loader. The report indicates the types of errors encountered to enable the submitting organization to make the necessary corrections and resubmit the data.

The header of the report indicates the Date of Generation, Lead Organization, Primary Contact, Protocol ID, Load Number, and Load Date.

The report groups the errors encountered by category:

- Rejection,
- Caution, and
- Cumulative

For each Rejection or Caution error, the report lists the:

- Error ID,
- Line Number,
- Table Name,
- Column Name,
- Column Value, and
- Error Location [the Primary Key(s) for the record]

For each Cumulative error, the report lists:

- Error ID,
- Table Name, and
- Column Value

The end of the report lists totals for each error category; it also summarizes the total number of records with and without errors (if applicable) by table name. Cumulative errors are not included in the summarized totals.

8.1.1. CDUS ERROR LOG REPORT COLUMN HEADINGS

8.1.1.1. Date of Generation

This date indicates the date the Smart Loader Error Log Report was produced.

8.1.1.2. Protocol ID

The Protocol ID is the protocol number for which data was loaded via the Smart Loader.

8.1.1.3. Load Number

The load reference number—the number of loads both submitted and loaded.

8.1.1.4. Load Date


The Load Date indicates the date the data were loaded into the system.

8.1.2. REPORT DETAIL

This section describes the specific type of data details that are available in the report.

8.1.2.1. Error ID

This is the identification number of the error. Each error generated by the Smart Loader has a predefined identification number. The format of these numbers is:



The first character indicates the Error Category. It can be Rejection (R), Caution (C), or Cumulative (D).

Please refer to the Smart Loader Error Description Report for a detailed error description corresponding to an error ID.

8.1.2.2. Line Number

This is the physical line number of the record in the submitted data file. The blank lines present in the file are also counted.

8.1.2.3. Table Name

This is the name of the table related to the current error. If the Smart Loader is unable to decide the table name (i.e., when table name itself is wrong), then this field will list “DEFAULT” as the table name.

8.1.2.4. Column Name

This is the name of the column related to the current error. This field is left blank if the column name is irrelevant or not unique in the current error context. For example, for the error “Wrong number of columns,” this field is left blank.

8.1.2.5. Column Value

This column contains the actual data values that were summarized in the data file. In case of a cumulative error, the column value corresponds to the record(s) existing in the active database, not those submitted with the current file.

8.1.2.6. Error Location

This field indicates the value of the Unique Record Identifiers (URI), or Primary Keys, for the current table. The names of the URI fields for the current record are listed in the section UNIQUE IDENTIFIERS FOR EACH TABLE LISTED IN THE ERROR REPORT. There is one-to-one mapping from the Name to the Value. For example, if Patient_ID is the first name listed, then the first value in the Error Location is the value of the Patient_ID.

If the Smart Loader is unable to find the URI for the current record, then the Error Location indicates the first four field values of the current record.

8.1.2.7. Unique Identifiers

This lists the field names which together uniquely identify a record in the table.

8.1.2.8. Error Category

There are three error categories associated with the Smart Loader. They are Rejection, Caution, and Cumulative.

8.1.2.9. Error Encountered

This lists the total number of errors encountered for an error category. This number is the count of the errors reported in the corresponding section.

8.2. ERROR DESCRIPTION REPORT

Descriptions of each error message displayed in the CDUS Error Log Report are listed by Error ID in the CDUS – Error Description Report (see Figure 3). As with the CDUS Error Log Report, the error descriptions in the CDUS – Error Description Report are grouped by category:

Rejection,


Caution, and

Cumulative

8.3. SAMPLE REPORTS

The following pages show a sample Error Log Report and Error Description Report with call out text describing each part of the reports.

FIGURE 2: CDUS Error Log Report



Note: Figures 2 and 3 are provided for explanatory purposes only, they are not exhaustive sets of error messages. Error Log Reports (Figure 2) specific to each data load and the Error Description Report will be mailed with data load results.

FIGURE 2: CDUS Error Log Report (cont.)


	Error Category : CAUTION No Caution Errors Encountered		Caution error category
	Error Category : CUMULATIVE No Cumulative Errors Encountered		Cumulative error category
UNIQUE IDENTIFIERS FOR EACH TABLE LISTED IN THE ERROR REPORT			

	Table Name	Unique Identifiers	
	-----	-----	
Table name	DEFAULT PATIENTS	[PATIENT_ID]	Unique identifier being listed
CDUS - Smart Loader Summary Report			

	Error Category	Errors Encountered	
	-----	-----	
Error category type	REJECTION	29	Total for each error type
	CAUTION	0	
	CUMULATIVE	0	

		Records Without Errors	Records With Errors
	-----	-----	-----
	COLLECTION	1	0
Table name	PATIENTS	0	29
	PUBLICATIONS	0	0
Summarized totals			

FIGURE 3: CDUS Error Description Report



Note: Figures 2 and 3 are provided for explanatory purposes only; they are not exhaustive sets of error messages. Error Log Reports (Figure 2) specific to each data load and the Error Description Report will be mailed with data load results.

9. CDUS BUSINESS RULES

The following table provides all the business rules effective as of the CDUS submission of October 2003.

Table I: CDUS Business Rules

Table Name	Column Name	Problem Type/Error Type	Error Type	Error Description
COLLECTIONS	SUBMISSION_DATE	Inappropriate Mandatory	REJECTION	Must be <= System Date
	CUTOFF_DATE	Inappropriate Mandatory	REJECTION	Must be <= System Date
	CUTOFF_DATE	Inappropriate Mandatory	REJECTION	Must be greater than or equal to the previous submission's CUTOFF_DATE
	CUTOFF_DATE	Inappropriate Mandatory	REJECTION	Must be <= SUBM_DATE
	CURRENT_TRIAL_STATUS_CODE	Inappropriate Mandatory	REJECTION	Status and Status_Date must Progress towards Completion or must be consistent with the CTEP database
	CURRENT_TRIAL_STATUS_CODE	Inappropriate Mandatory	REJECTION	Protocol Status must not be Approved if Patients are being accrued
	CURRENT_TRIAL_STATUS_DATE	Incomplete Mandatory	REJECTION	Mandatory Column is NULL
	CURRENT_TRIAL_STATUS_DATE	Inappropriate Mandatory	REJECTION	Must be <= System Date
	LEAD_ORG_ID	Inconsistent Mandatory	REJECTION	Mandatory data not consistent with previous value
CORRELATIVE_STUDIES	PATIENTS_COLLECTED	Incomplete Mandatory	REJECTION	Mandatory field is NULL
	PATIENTS_COLLECTED	Inappropriate Mandatory	CAUTION	Value must not decrease over time
	PATIENTS_COLLECTED	Inappropriate Mandatory	REJECTION	Must be >= PATIENTS_ANALYZED
	PATIENTS_COLLECTED	Inappropriate Mandatory	REJECTION	Must be <= SAMPLES_COLLECTED
	PATIENTS_ANALYZED	Incomplete Mandatory	REJECTION	Mandatory field is NULL
	PATIENTS_ANALYZED	Inappropriate Mandatory	CAUTION	Value must not decrease over time
	PATIENTS_ANALYZED	Inappropriate Mandatory	REJECTION	Must be <= SAMPLES_ANALYZED
	SAMPLES_COLLECTED	Incomplete Mandatory	REJECTION	Mandatory for all studies Activated on or after 01/01/2002
	SAMPLES_COLLECTED	Inappropriate Mandatory	CAUTION	Value must not decrease over time
	SAMPLES_COLLECTED	Inappropriate Mandatory	REJECTION	Must >= SAMPLES_ANALYZED
	SAMPLES_ANALYZED	Incomplete Mandatory	REJECTION	Mandatory for all studies Activated on or after 01/01/2002
	SAMPLES_ANALYZED	Inappropriate Mandatory	CAUTION	Value must not decrease over time
	ALL COLUMN NAMES	Incomplete Mandatory	REJECTION	Correlative Study information Mandatory if Correlative ID abstracted
PUBLICATIONS	MEDLINE_UID	Inconsistent Requested	CAUTION	Data not consistent with previous value
	TITLE	Incomplete Requested	CAUTION	Requested when MEDLINE_UID is NULL
	TITLE	Inconsistent Requested	CAUTION	Data not consistent with previous value
	JOURNAL	Incomplete Requested	CAUTION	Requested when MEDLINE_UID is NULL
	JOURNAL	Inconsistent Requested	CAUTION	Data not consistent with previous value

Table Name	Column Name	Problem Type/Error Type	Error Type	Error Description
PUBLICATIONS (cont.)	VOLUME	Incomplete Requested	CAUTION	Requested when MEDLINE_UID is NULL
	VOLUME	Inconsistent Requested	CAUTION	Data not consistent with previous value
	YEAR	Incomplete Requested	CAUTION	Requested when MEDLINE_UID is NULL
	YEAR	Inconsistent Requested	CAUTION	Data not consistent with previous value
	PUBLISHER	Incomplete Requested	CAUTION	Requested when MEDLINE_UID is NULL
	PUBLISHER	Inconsistent Requested	CAUTION	Data not consistent with previous value
	PAGES	Incomplete Requested	CAUTION	Requested when MEDLINE_UID is NULL
	PAGES	Inconsistent Requested	CAUTION	Data not consistent with previous value
AUTHORS	FNAME	Incomplete Requested	CAUTION	Requested field is NULL
	FNAME	Inconsistent Requested	CAUTION	Data not consistent with previous value
	LNAME	Incomplete Requested	CAUTION	Requested field is NULL
	LNAME	Inconsistent Requested	CAUTION	Data not consistent with previous value
PATIENTS	ZIP_CODE	Incomplete Requested	CAUTION	Requested field is NULL (when COUNTRY_CODE is NULL and ZIP_CODE is NULL)
	ZIP_CODE	Incomplete Requested	CAUTION	Requested when COUNTRY_CODE = 'US'
	ZIP_CODE	Inconsistent Requested	CAUTION	Data not consistent with previous value
	BIRTH_DATE	Incomplete Mandatory	REJECTION	Mandatory field is NULL
	BIRTH_DATE	Incomplete Requested	CAUTION	Requested field is NULL
	BIRTH_DATE	Inappropriate Mandatory	REJECTION	Must be <= CUTOFF_DATE
	BIRTH_DATE	Inappropriate Mandatory	REJECTION	Patient age must be <=100 at Date of Entry
	BIRTH_DATE	Inappropriate Mandatory	REJECTION	Must be <= DATE_OF_ENTRY
	BIRTH_DATE	Inconsistent Mandatory	CAUTION	Data not consistent with previous value
	GENDER_CODE	Incomplete Mandatory	REJECTION	Mandatory field is NULL
	GENDER_CODE	Inconsistent Mandatory	CAUTION	Data not consistent with previous value
	RACE_CODE	Inconsistent Requested	CAUTION	Data not consistent with previous value
	ETHNICITY_FLAG	Incomplete Mandatory	REJECTION	Mandatory field is NULL
	METHOD_OF_PAYMENT	Incomplete Requested	CAUTION	Requested field in NULL
	DATE_OF_ENTRY	Inappropriate Mandatory	REJECTION	Must be <= CUTOFF_DATE
	DATE_OF_ENTRY	Inappropriate Mandatory	REJECTION	Must be >= date where protocol status became 'AC' (Active) - Min AC Date
	DATE_OF_ENTRY	Inappropriate Mandatory	REJECTION	Date of Entry must be within the date range when the protocol was Active
	DATE_OF_ENTRY	Inappropriate Mandatory	REJECTION	Must be <= SUBM_DATE
	DATE_OF_ENTRY	Inconsistent Mandatory	CAUTION	Data not consistent with previous value
	REG_GROUP_ID	Incomplete Mandatory	REJECTION	Mandatory for intergroup trials
	REG_GROUP_ID	Inappropriate Mandatory	REJECTION	Must be a participant on protocol
	REG_GROUP_ID	Inconsistent Mandatory	CAUTION	Data not consistent with previous value
	REG_INST_ID	Incomplete Mandatory	REJECTION	Mandatory field is NULL

Table Name	Column Name	Problem Type/Error Type	Error Type	Error Description
PATIENTS (cont.)	REG_INST_ID	Inconsistent Mandatory	CAUTION	Data not consistent with previous value
	TX_ON_STUDY	Inappropriate Mandatory	REJECTION	If TX_On_Study = '1' (Yes), Off_Study_Reason MUST be NULL
	TX_ON_STUDY	Incomplete Mandatory	REJECTION	Requested when the study has been assigned to CDUS-Complete
	OFF_TX_REASON	Incomplete Mandatory	REJECTION	Best Response for Progression is mandatory when OFF_TX_REASON = '02'
	OFF_TX_REASON	Incomplete Mandatory	REJECTION	Mandatory when TX_ON_STUDY = '2'
	OFF_TX_REASON	Inappropriate Mandatory	REJECTION	OFF_TX_REASON must be NULL if TX_ON_STUDY = '1'
	OFF_TX_REASON	Inappropriate Mandatory	REJECTION	If Off_Treatment_Reason = '04' (Death); then at least 1 AE MUST be grade 5 (Death)
	OFF_TX_REASON	Inappropriate Mandatory	REJECTION	Must be NULL if TX_ON_STUDY = '1'
	OFF_TX_REASON	Inconsistent Mandatory	CAUTION	Data not consistent with previous value
	LAST_TX_DATE	Incomplete Mandatory	REJECTION	Mandatory when TX_ON_STUDY = '2'; CDUS-Complete; study activated on or after 01/01/2002; and Off_TX_Reason is not Code 06, 12, or 13
	LAST_TX_DATE	Inappropriate Mandatory	REJECTION	Must be NULL if TX_ON_STUDY = '1'; CDUS-Complete; and study activated on or after 01/01/2002
	LAST_TX_DATE	Inappropriate Mandatory	REJECTION	Must be >= DATE_OF_ENTRY
	LAST_TX_DATE	Inconsistent Mandatory	CAUTION	Data not consistent with previous value
	OFF_STUDY_REASON	Inappropriate Mandatory	REJECTION	Off_Study_Reason MUST be NULL if TX_On_Study = '1' (Yes)
	OFF_STUDY_REASON	Inappropriate Mandatory	REJECTION	If Off_Study_Reason = '04' (Death); then at least 1 AE MUST be grade 5 (Death)
	OFF_STUDY_REASON	Inappropriate Mandatory	REJECTION	Off_Study_Reason MUST be '04' (Death) if Off_Treatment_Reason = '04' (Death)
	OFF_STUDY_REASON	Incomplete Mandatory	REJECTION	Mandatory if OFF_STUDY_DATE is NOT NULL
	OFF_STUDY_DATE	Incomplete Mandatory	REJECTION	Mandatory if OFF_STUDY_REASON is NOT NULL
	SUBGROUP_CODE	Incomplete Mandatory	REJECTION	Mandatory when the study has been assigned to CDUS-Complete
	SUBGROUP_CODE	Inconsistent Mandatory	CAUTION	Data not consistent with previous value
	INELIGIBILITY_STATUS	Incomplete Mandatory	REJECTION	Mandatory when the study has been assigned to CDUS-Complete
	BASELINE_PS_CODE	Incomplete Requested	CAUTION	Requested when the study has been assigned to CDUS-Complete
	PRIOR_CHEMO_REGS	Incomplete Requested	CAUTION	Requested when the study has been assigned to CDUS-Complete
	PRIOR_CHEMO_REGS	Inconsistent Requested	CAUTION	Data not consistent with previous value
	DISEASE_CODE	Incomplete Mandatory	REJECTION	Mandatory when it is a Phase I trial with DCTD-supplied investigational agent
	DISEASE_CODE	Inconsistent Mandatory	CAUTION	Data not consistent with previous value
	RESP_EVAL_STATUS	Incomplete Mandatory	REJECTION	Mandatory when the study has been assigned to CDUS-Complete
	RESP_EVAL_STATUS	Incomplete Mandatory	REJECTION	Best response record mandatory when RESP_EVAL_STATUS = '1'
	BASELINE_ABNORMALITIES_FLAG	Incomplete Mandatory	REJECTION	Mandatory when CDUS-Complete and Activated on or after 01/01/2002
	BASELINE_ABNORMALITIES_FLAG	Incomplete Mandatory	REJECTION	Baseline Abnormalities information Mandatory if BASELINE_ABNORMALITIES_FLAG = '1' = 'Yes'
	BASELINE_ABNORMALITIES_FLAG	Inappropriate Mandatory	REJECTION	Must be 'Yes' if PATIENT_ABNORMALITY information is entered and ABNORMALITY_TYPE = 'Baseline'
	BASELINE_ABNORMALITIES_FLAG	Inconsistent Mandatory	CAUTION	Data not consistent with previous value

Table Name	Column Name	Problem Type/Error Type	Error Type	Error Description
PATIENT_RACES	RACE_CODE	Incomplete Mandatory	REJECTION	Primary Key is NULL
	RACE_CODE	Inconsistent Mandatory	CAUTION	Data not consistent with previous value
	ALL COLUMN NAMES	Incomplete Mandatory	REJECTION	PATIENT_RACES record Mandatory if patient record exists
PRIOR_THERAPIES	THERAPY_CODE	Incomplete Mandatory	REJECTION	Primary Key is NULL
TREATMENT_COURSES	COURSE_START_DATE	Incomplete Requested	CAUTION	Requested when the study has been assigned to CDUS-Complete
	COURSE_START_DATE	Incomplete Mandatory	REJECTION	Mandatory data not submitted
	COURSE_START_DATE	Inappropriate Mandatory	REJECTION	Must be >= DATE_OF_ENTRY
	COURSE_START_DATE	Inappropriate Mandatory	REJECTION	Course_Start_Date MUST be <= Last_TX_Date
	TX_ASGMNT_CODE	Incomplete Mandatory	REJECTION	Mandatory when the study has been assigned to CDUS-Complete
	TX_ASGMNT_CODE	Inconsistent Mandatory	CAUTION	Data not consistent with previous value
	TREATING_INST_ID	Incomplete Requested	CAUTION	Requested when the study has been assigned to CDUS-Complete
	TREATING_INST_ID	Inconsistent Requested	CAUTION	Data not consistent with previous value
	HEIGHT	Incomplete Requested	CAUTION	Requested when the study has been assigned to CDUS-Complete
	HEIGHT	Inappropriate requested	CAUTION	Must be >= 25cm and <= 200cm
	HEIGHT	Inconsistent Requested	CAUTION	Data not consistent with previous value
	WEIGHT	Incomplete Requested	CAUTION	Requested when the study has been assigned to CDUS-Complete
	WEIGHT	Inappropriate requested	CAUTION	Must be >= 3kg and <= 120kg
	WEIGHT	Inconsistent Requested	CAUTION	Data not consistent with previous value
	TOX_EXPERIENCED	Inconsistent Mandatory	WARNING	Mandatory data not consistent with previous value (Inactive)
	AE_EXPERIENCED	Incomplete Mandatory	REJECTION	Adverse Event records mandatory when AE_EXPERIENCED = '1'
	AE_EXPERIENCED	Incomplete Mandatory	REJECTION	Mandatory when the study has been assigned to CDUS-Complete
COURSE_AGENTS	DOSE_CHANGE	Incomplete Requested	CAUTION	Requested when the study has been assigned to CDUS-Complete
	DOSE_CHANGE	Inconsistent Requested	CAUTION	Data not consistent with previous value
	DOSE_AMOUNT	Incomplete Requested	CAUTION	Requested when the study has been assigned to CDUS-Complete
	DOSE_AMOUNT	Inconsistent Requested	CAUTION	Data not consistent with previous value
	UNIT_CODE	Incomplete Requested	CAUTION	Requested when the study has been assigned to CDUS-Complete
	UNIT_CODE	Inconsistent Requested	CAUTION	Data not consistent with previous value
BASELINE_ABNORMALITIES	AE_OTHER_SPECIFY	Incomplete Mandatory	REJECTION	Mandatory when AE_TYPE_CODE = 'other'
	TOX_GRADE_CODE	Incomplete Mandatory	REJECTION	Mandatory when BASELINE_ABNORMALITIES_FLAG = 'Yes' (Mandatory when TOX_TYPE_CODE is not NULL)
	ALL COLUMN NAMES	Incomplete Mandatory	REJECTION	Mandatory when BASELINE_ABNORMALITIES_FLAG = 'Yes'
	ALL COLUMN NAMES	Inappropriate Mandatory	REJECTION	Baseline Abnormality Records may only be submitted if BASELINE_ABNORMALITIES_FLAG = 'Yes'
ADVERSE_EVENTS	AE_OTHER_SPECIFY	Incomplete Mandatory	REJECTION	Mandatory when AE_TYPE_CODE = 'other'; CDUS-Complete; and Activated on or after 01/01/2002
	AE_OTHER_SPECIFY	Incomplete Mandatory	REJECTION	Mandatory when CDUS-Complete and Activated on or after 01/01/2002
	AE_ATTRIBUTION_CODE	Incomplete Mandatory	REJECTION	Mandatory when AE_EXPERIENCED = '1'

Table Name	Column Name	Problem Type/Error Type	Error Type	Error Description
ADVERSE_EVENTS (cont.)	AE_ATTRIBUTION_CODE	Inconsistent Mandatory	Caution	Data not consistent with previous value
	AE_GRADE_CODE	Inappropriate Mandatory	REJECTION	If AE_Grade_Code = '5' (Death); then either Off_TX_Reason or Off_Study_Reason MUST be '04' (Death)
	AER_FILED	Incomplete Mandatory	REJECTION	Mandatory when AE_EXPERIENCED = '1'
	ALL COLUMN NAMES	Inappropriate Mandatory	REJECTION	Adverse Event record can only be submitted when AE_EXPERIENCED = '1'
LATE_ADVERSE_EVENTS	AE_OTHER_SPECIFY	Incomplete Mandatory	REJECTION	Mandatory when AE_TYPE_CODE = 'other'
	AE_START_DATE	Inappropriate Mandatory	REJECTION	AE_Start_Date MUST be greater than the Last_TX_Date
BEST_RESPONSES	ALL COLUMN NAMES	Incomplete Mandatory	REJECTION	Mandatory when RESP_EVAL_STATUS = '1'
	ALL COLUMN NAMES	Incomplete Mandatory	REJECTION	BEST_RESPONSES records can only be submitted when RESP_EVAL_STATUS = '1'
	CATEGORY	Incomplete Mandatory	REJECTION	Best Response for Progression is mandatory when OFF_TX_REASON = '02'
	CATEGORY	Inappropriate Mandatory	REJECTION	Treatment course record mandatory when BEST_RESPONSES record exists
	CATEGORY	Inappropriate Mandatory	REJECTION	Value may not decline except to Progression
	OBSERVED_DATE	Incomplete Mandatory	REJECTION	Mandatory Column is NULL
	OBSERVED_DATE	Inappropriate Mandatory	REJECTION	Must be >= first COURSE_START_DATE
	OBSERVED_DATE	Inappropriate Mandatory	REJECTION	OBSERVED_DATE <= CUTOFF_DATE
TRIAL_COMMENTS	SUBGROUP_CODE	Incomplete Mandatory	REJECTION	Mandatory when TX_ASGNMT_CODE is NULL
	TX_ASGNMT_CODE	Incomplete Mandatory	REJECTION	Mandatory when SUBGROUP_CODE is NULL
	GEN_RESPONSE_COMMENTS	Incomplete Mandatory	REJECTION	Mandatory when BEST_RESPONSES.CATEGORY = '98' (Other); CDUS-Complete; Activated on or after 01/01/2002
PHASE1_END_POINTS	TX_ASGNMT_CODE	Incomplete Requested	CAUTION	Requested when it is a Phase 1 trial with a DCTD-supplied investigational agent
PHASE1_END_POINT_DLTS	TX_ASGNMT_CODE	Incomplete Requested	CAUTION	Requested when it is a Phase 1 trial with a DCTD-supplied investigational agent
	TOX_TYPE_CODE	Incomplete Mandatory	REJECTION	Mandatory when it is a Phase 1 trial with a DCTD-supplied investigational agent

INDEX

A

abbreviated data set, 1, 2, 3, 4, 5, 6, 15, 19
 abnormal laboratory finding, 32
 accepted report, 57
 accrual, 1, 5, 6, 7, 10, 11, 13
 activation date, 10, 14, 56
 additions since the last report, 7, 12
 administrative data, 2, 10, 12, 23
 adverse event, 3, 4, 8, 17, 18, 23, 24, 27, 29, 30, 32, 33, 34, 35, 36, 37, 41, 51, 52, 70, 71
 ADVERSE_EVENTS Table, 47
 AE_Attribution_Code
 ADVERSE_EVENTS Table, 47
 LATE_ADVERSE_EVENTS Table, 48
 AE_ Experienced
 TREATMENT_COURSES Table, 46
 AE_Grade_Code
 ADVERSE_EVENTS Table, 47
 BASELINE_ABNORMALITIES Table, 47
 LATE_ADVERSE_EVENTS Table, 48
 AE_Other_Specify
 ADVERSE_EVENTS Table, 47
 BASELINE_ABNORMALITIES Table, 47
 LATE_ADVERSE_EVENTS Table, 48
 PHASE1_END_POINT_DLTS Table, 49
 AE_Start_Date
 LATE_ADVERSE_EVENTS Table, 48
 AE_Type_Code
 ADVERSE_EVENTS Table, 47
 BASELINE_ABNORMALITIES Table, 47
 LATE_ADVERSE_EVENTS Table, 47
 PHASE1_END_POINT_DLTS Table, 49
 AER_Filed
 ADVERSE_EVENTS Table, 47
 age, 9, 15
 agent, 32
 active treatment, 24
 administered, 3, 27, 32
 attribution, 36
 commercial, 1, 4, 24
 course, 41
 DCTD-supplied, 1, 4, 9, 17, 23, 30, 32, 37, 69, 71
 dose, 31
 IND, 7, 11, 59
 no longer needed for study, 11
 non-NCI, 1, 4
 prior therapy, 26, 27
 received by patient, 31
 single or multi-agent, 26, 27, 32
 suspended from receiving, 59

Agent_ID
 COURSE_AGENTS Table, 46
 amended
 accrual, 13
 closure date, 14
 analyzed
 patient, 16
 sample, 16
 approval process, 55
 approved report, 57
 arm, 9, 15
 article, 18, 19
 attribution, 32, 33, 34, 36, 37
 author, 18
 Author_Name
 AUTHORS Table, 44
 Author_Order
 AUTHORS Table, 44
 AUTHORS Table, 44

B

baseline abnormality, 29, 70
 baseline performance status, 25
 BASELINE_ABNORMALITIES Table, 47
 Baseline_Abnormalities_Flag
 PATIENTS Table, 45
 Baseline_PS_Code
 PATIENTS Table, 45
 BEST_RESPONSES Table, 48
 bio-marker, 5
 Birth_Date
 PATIENTS Table, 44
 business rules, 57, 67

C

cancer center, 4, 5
 cancer control, 5
 cancer prevention, 5
 category
 error, 61, 62
 response, 38
 Category
 BEST_RESPONSES Table, 48
 caution, 58, 59
 CCOP, 5, 31
 CDUS data set, 3, 4, 5
 CDUS web site, 8
 change code, 12
 change in dose, 32
 Change_Code
 COLLECTIONS Table, 43
 changes since the last report, 12
 chemo-prevention, 5
 chemotherapy, 26
 citation, 18
 Clinical Trials Monitoring Branch, 23, 31, 59
 closure date, 14
 code
 change, 12
 protocol, 8
 race, 20
 registering institution, 2, 22
 subgroup, 14, 16, 17
 treating institution, 31
 collected
 patient, 16
 sample, 16
 COLLECTIONS Table, 42
 column name, 51, 60, 62, 67
 column value, 60, 62
 complete data submission, 1, 3, 4, 5
 Completer_Email
 COLLECTIONS Table, 43
 Completer_FAX
 COLLECTIONS Table, 43
 Completer_Name
 COLLECTIONS Table, 43
 Completer_Phone
 COLLECTIONS Table, 43
 conclusions, 16
 continuing care, 5
 cooperative group, 2, 4, 5, 11, 22, 23, 31
 correction process, 55, 58
 correlative study, 8, 15, 16, 41, 67
 CORRELATIVE_STUDIES Table, 43
 Correlative_Study_ID
 CORRELATIVE_STUDIES Table, 43
 Country_Code
 PATIENTS Table, 44
 course, 30, 32, 33, 34
 identification, 30
 start date, 30
 course (cycle), 30
 COURSE_AGENTS Table, 46
 Course_ID
 ADVERSE_EVENTS Table, 47
 COURSE_AGENTS Table, 46
 TREATMENT_COURSES Table, 46
 Course_Start_Date
 TREATMENT_COURSES Table, 46
 CTCAE, 17, 29, 30, 34, 35, 37, 54
 CTMB, 23, 31, 59
 CTMS monitored trials, 3
 cumulative data, 56
 cumulative error, 59
 current trial status, 11
 current trial status date, 11
 Current_Trial_Status_Code
 COLLECTIONS Table, 43
 Current_Trial_Status_Date
 COLLECTIONS Table, 43
 cut-off date, 10
 CutOff_Date
 COLLECTIONS Table, 42
 cytogenetics, 5

registering institution, 2, 22
 subgroup, 14, 16, 17
 treating institution, 31
 collected
 patient, 16
 sample, 16
 COLLECTIONS Table, 42
 column name, 51, 60, 62, 67
 column value, 60, 62
 complete data submission, 1, 3, 4, 5
 Completer_Email
 COLLECTIONS Table, 43
 Completer_FAX
 COLLECTIONS Table, 43
 Completer_Name
 COLLECTIONS Table, 43
 Completer_Phone
 COLLECTIONS Table, 43
 conclusions, 16
 continuing care, 5
 cooperative group, 2, 4, 5, 11, 22, 23, 31
 correction process, 55, 58
 correlative study, 8, 15, 16, 41, 67
 CORRELATIVE_STUDIES Table, 43
 Correlative_Study_ID
 CORRELATIVE_STUDIES Table, 43
 Country_Code
 PATIENTS Table, 44
 course, 30, 32, 33, 34
 identification, 30
 start date, 30
 course (cycle), 30
 COURSE_AGENTS Table, 46
 Course_ID
 ADVERSE_EVENTS Table, 47
 COURSE_AGENTS Table, 46
 TREATMENT_COURSES Table, 46
 Course_Start_Date
 TREATMENT_COURSES Table, 46
 CTCAE, 17, 29, 30, 34, 35, 37, 54
 CTMB, 23, 31, 59
 CTMS monitored trials, 3
 cumulative data, 56
 cumulative error, 59
 current trial status, 11
 current trial status date, 11
 Current_Trial_Status_Code
 COLLECTIONS Table, 43
 Current_Trial_Status_Date
 COLLECTIONS Table, 43
 cut-off date, 10
 CutOff_Date
 COLLECTIONS Table, 42
 cytogenetics, 5

D

data
 administrative, 10, 12
 cumulative, 56
 cut-off date, 10

- due date, 10
- elements, 10
- inappropriate, 56
- incomplete, 56
- inconsistent, 56
- incorrect, 56
- mandatory, 55
- optional, 55
- patient-specific, 19
- requested, 55
- set, 1, 2, 3, 4, 5
- submission
 - abbreviated, 1, 2, 3, 4, 5
 - complete, 1, 3, 4, 5
 - date report submitted, 2, 10
 - duration, 7
 - first CDUS submission date, 6
 - frequency, 6
 - methods of, 7
 - person completing report, 2, 12
 - what data is submitted, 1
 - when is data submitted, 6
 - who submits data, 1
- data model, 40
- date
 - amended closure, 14
 - closure, 14
 - course start, 30
 - current trial status, 11
 - cut-off, 10
 - error log, 61
 - first CDUS submission, 6
 - last treatment, 24
 - load, 61
 - off study, 23, 24
 - patient entry, 2, 22
 - planned closure, 14
 - projected closure, 14
 - protocol activation, 10, 14, 56
 - report, 2, 10
 - response (observed), 38
- Date_Of_Entry
 - PATIENTS Table, 44
- DCP, 1, 5
- DCTD, 1
- DCTD-supplied investigational
 - agents, 3, 4
- demographic, 19
- description
 - subgroup, 9, 15
 - treatment assignment, 9
- disapproval process, 55
- disease, 9, 15
- Disease_Code
 - PATIENTS Table, 45
- Division of Cancer Prevention, 1
- Division of Cancer Treatment and
 - Diagnosis, 1
- dose, 16, 18, 31, 32
 - escalation or de-escalation, 32
- dose level, 9, 15
- dose modification, 32
- Dose_Amount
 - COURSE_AGENTS Table, 46
- Dose_Change
 - COURSE_AGENTS Table, 46
- due date, 10
- duration of data submission, 7

E

- early detection, 5
- e-mail address, 2, 12
- end points, 16
- error, 58, 59, 60
 - category, 61, 62
 - column name, 51, 60, 62, 67
 - column value, 60, 62
 - description report, 61, 62, 63, 64, 66
 - encountered, 62
 - ID, 60, 61, 62
 - line number, 60, 61
 - location, 60, 62
 - table name, 41, 51, 60, 61, 67
 - unique identifier, 62
- error log, 57, 60, 61, 62, 63, 64, 66
- error notices, 58
- ethnicity, 20
- Ethnicity_Flag
 - PATIENTS Table, 44
- evaluative for response, 37
- evaluation status, 29

F

- fax number, 2, 12
- file format, 41
- findings
 - correlative study, 16
- Findings
 - CORRELATIVE_STUDIES Table, 43
- FTP site, 7
- funding, 12

G

- Gen_AE_Comments
 - TRIAL_COMMENTS Table, 48
- Gen_Response_Comments
 - TRIAL_COMMENTS Table, 48
- Gender_Code
 - PATIENTS Table, 44
- grade, 29, 33, 34, 35, 37, 47, 48, 54, 71
- grant, 4, 5, 12

H

- Height
 - TREATMENT_COURSES Table, 46

I

- identification
 - citation, 18
 - cooperative group, 11
 - correlative study, 15
 - course, 30
 - error, 60, 61, 62
 - institution, 11
 - patient, 19
 - protocol, 61
 - publication, 18
 - subgroup, 9
- inappropriate data, 56
- incomplete data, 56
- inconsistent data, 56
- incorrect data, 56
- ineligibility status, 25

- Ineligibility_Status
 - PATIENTS Table, 45
- institution, 2, 4, 5, 11, 22, 31
- investigational agent, 31, 32
- investigator, 12

J

- journal, 18
- Journal
 - PUBLICATIONS Table, 44

L

- laboratory, 15
- last treatment, 24
- Last_TX_Date
 - PATIENTS Table, 45
- late adverse event, 37
- LATE_ADVERSE_EVENTS Table, 47
- lead institution/group, 11
- letters, 59
- line number, 60, 61
- load
 - date, 61
 - number, 61
- location of error, 60, 62

M

- malignancy, 37
- mandatory data, 55
- MedDRA, 27
- Medline UID, 18
- Medline_UID
 - PUBLICATIONS Table, 43
- Method_Of_Payment
 - PATIENTS Table, 44
- methods of data submission, 7
- minimum effective dose, 16
- modification of dose, 32

N

- name
 - author, 18
 - column, 51, 60, 62, 67
 - person completing report, 12
 - principal investigator, 12
 - table, 41, 51, 60, 61, 67
- NCI protocol number, 10
- non-CTMS monitored trials, 4
- non-group trial, 4, 5, 22, 31
- non-treatment trial, 5
- NSC number, 32
- number
 - investigator, 12
 - line, 60, 61
 - load, 61
 - page, 19
 - prior chemotherapy regimens, 26
 - protocol, 10
 - volume, 19

O

- observed date, 38
- Observed_Date
 - BEST_RESPONSES Table, 48
- off_treatment, 23
- off study, 23, 24
- Off_Study_Date

- PATIENTS Table, 45
- Off_Study_Reason
 - PATIENTS Table, 45
- Off_TX_Reason
 - PATIENTS Table, 45
- on study, 23
- optional data, 55
- other, specify, 17, 29, 35, 37
- overview, 1, 55

P

- page, 19
- Pages
 - PUBLICATIONS Table, 44
- pain control, 5
- patient
 - accrual, 13
 - administrative items, 23
 - adverse event, 32, 34
 - age, 9, 15
 - analyzed, 16
 - collected, 16
 - date of entry, 2, 22
 - demographic items, 19
 - dose received, 31
 - identification, 19
 - malignancy, 37
 - per month (rate), 13
 - prior therapy, 9, 15
 - specific data, 19
 - stratified by disease, 9, 15
 - stratified by other classification, 9, 15
 - treatment, 30
- Patient_ID
 - ADVERSE_EVENTS Table, 47
 - BASELINE_ABNORMALITIES Table, 47
 - BEST_RESPONSES Table, 48
 - COURSE_AGENTS Table, 46
 - LATE_ADVERSE_EVENTS Table, 47
 - PATIENT_RACES Table, 45
 - PATIENTS Table, 44
 - PRIOR_THERAPIES Table, 45
 - TREATMENT_COURSES Table, 46
- PATIENT_RACES Table, 3, 45
- PATIENTS Table, 44
- Patients_Analyzed
 - CORRELATIVE_STUDIES Table, 43
- Patients_Collected
 - CORRELATIVE_STUDIES Table, 43
- person completing the report, 2, 12
- pharmacokinetic, 5, 15
- Phase 1, 3, 4, 16
- Phase 2, 4, 16
- Phase 3, 4
- PHASE1_END_POINT_DLTS Table, 49
- PHASE1_END_POINTS Table, 49
- planned
 - accrual rate, 13
 - closure date, 14
- primary institution/group, 11
- principal investigator, 12
- prior chemotherapy, 26
- prior therapy, 9, 15, 26, 27, 28

- Prior_Chemo_Regs
 - PATIENTS Table, 45
- PRIOR_THERAPIES Table, 45, 46
- projected closure date, 14
- protocol
 - activation date, 10, 14, 56
 - code information, 8
 - number, 10
 - submission worksheet, 8, 12, 14, 15
 - title, 10
- protocol ID, 61
- Protocol_ID
 - ADVERSE_EVENTS Table, 47
 - AUTHORS Table, 44
 - BASELINE_ABNORMALITIES Table, 47
 - BEST_RESPONSES Table, 48
 - COLLECTIONS Table, 42
 - CORRELATIVE_STUDIES Table, 43
 - COURSE_AGENTS Table, 46
 - LATE_ADVERSE_EVENTS Table, 47
 - PATIENT_RACES Table, 45
 - PATIENTS Table, 44
 - PHASE1_END_POINT_DLTS Table, 49
 - PHASE1_END_POINTS Table, 49
 - PRIOR_THERAPIES Table, 45
 - PUBLICATIONS Table, 43
 - TREATMENT_COURSES Table, 46
 - TRIAL_COMMENTS Table, 48
- PSW, 8, 12, 14, 15
- publication, 18, 41, 43, 44
- Publication_ID
 - AUTHORS Table, 44
 - PUBLICATIONS Table, 43
- PUBLICATIONS Table, 43
- publisher, 19
- Publisher
 - PUBLICATIONS Table, 44

Q

- quality of life, 5

R

- race, 20
- Race_Code
 - PATIENT_RACES Table, 45
- rate, 13
- reason
 - off study, 23, 24
 - off treatment, 23
- recommended dose, 16
- Reg_Group_ID
 - PATIENTS Table, 44
- Reg_Inst_ID
 - PATIENTS Table, 44
- registering group/institution, 2, 22
- rehabilitation, 5
- rejection, 57, 58
- relation between entities, 41
- report
 - additions or changes, 12
 - adverse event, 8, 32, 33, 34, 36
 - approval, 57

- caution, 58
- correction process, 58
- cumulative error, 59
- cut-off date, 10
- dates, 2, 10
- detail, 61
- disapproval, 57
- due date, 10
- error, 60
- error description report, 61, 62, 63, 64, 66
- error log, 57, 60, 61, 62, 63, 64, 66
- person completing, 2, 12
- rejection, 58
- respond to a caution, 59
- sample, 63
- submitting, 2, 10
- requested data, 55
- research base, 4, 5
- Resp_Eval_Status
 - PATIENTS Table, 45
- respond
 - to a caution notice, 59
 - to a cumulative error, 59
- response, 18, 37, 38
- response evaluation status, 29
- results, 57

S

- sample analyzed, 16
- sample collected, 16
- sample file, 50
- sample reports, 63
- Samples_Analyzed
 - CORRELATIVE_STUDIES Table, 43
- Samples_Collected
 - CORRELATIVE_STUDIES Table, 43
- site
 - CDUS web, 8
 - FTP, 7
- start date
 - course, 30
 - late adverse event, 37
- status
 - baseline performance, 25
 - ineligibility, 25
 - response evaluation, 29
 - treatment, 23
 - trial, 11
 - trial date, 11
- stratified, 9, 15
- study, off, 23, 24
- subgroup, 9, 14, 15, 16, 17, 18, 25, 55
- Subgroup_Code
 - PATIENTS Table, 45
 - PHASE1_END_POINT_DLTS Table, 49
 - PHASE1_END_POINTS Table, 49
 - TRIAL_COMMENTS Table, 48
- Subm_Date
 - COLLECTIONS Table, 42
- submission, 6, 7
- submission results, 57
- successful report, 57
- summary, 10, 17

suspension, 59
symptom management, 5

T

table

ADVERSE_EVENTS, 47
AUTHORS, 44
BASELINE_ABNORMALITIES, 47
BEST_RESPONSES, 48
COLLECTIONS, 42
CORRELATIVE_STUDIES, 43
COURSE_AGENTS, 46
LATE_ADVERSE_EVENTS, 47
PATIENT_RACES, 3, 45
PATIENTS, 44
PHASE1_END_POINT_DLTS, 49
PHASE1_END_POINTS, 49
PRIOR_THERAPIES, 45, 46
PUBLICATIONS, 43
TREATMENT_COURSES, 46
TRIAL_COMMENTS, 48
table name, 41, 51, 60, 61, 67
TAC/TAD, 9, 14, 15, 17, 18, 30
telephone number, 12
therapy, 26, 27, 28, 34
Therapy_Code
PRIOR_THERAPIES Table, 45
title
article, 18
correlative study, 15
protocol, 10
publication, 18
Title
PUBLICATIONS Table, 43
total dose, 32
Total Dose of the Investigational Agent Administered per Course, 32
total planned accrual, 13
treating institution code, 31
Treating_Inst_ID
TREATMENT_COURSES Table, 46
treatment
assignment, 9, 14, 15, 17, 18, 30
last treatment date, 24
off treatment reason, 23

patient by course, 30
status, 23
TREATMENT_COURSES Table, 46
trial
bio-marker, 5
cancer center, 4, 5
categories, 3
chemo-prevention, 5
comments, 17
continuing care, 5
control, 5
cooperative group, 4, 23, 31
correlative, 8, 15, 16, 41, 67
CTMS monitored, 3
cytogenetics, 5
early detection, 5
institution, 4, 5
non-CTMS monitored, 4
non-group, 4, 5, 22, 31
non-treatment, 5
cancer center, 5
CCOP, 5
cooperative group, 5
institution, 5
research base, 5
pain control, 5
pharmacokinetic, 5
Phase 1, 3, 4, 16, 17, 30
Phase 2, 4, 16, 17, 30
Phase 3, 4
prevention, 5
quality of life, 5
rehabilitation, 5
research base, 4
status, 11
status date, 11
symptom management, 5
that do not include a NCI Grant, 5
that do not include DCTD-supplied investigational agents, 4, 5
that include DCTD-investigational agents, 3
that include DCTD-supplied investigational agents, 3, 4
treatment, 3
TRIAL_COMMENTS Table, 48
TX_Asgmnt_Code

PHASE1_END_POINT_DLTS Table, 49
PHASE1_END_POINTS Table, 49
TREATMENT_COURSES Table, 46
TRIAL_COMMENTS Table, 48
TX_On_Study PATIENTS Table, 45
type
adverse event, 34, 35
error notices, 58
prior therapy, 27

U

unique identifier, 62
Unit_Code
COURSE_AGENTS Table, 46
units, 32

V

valid values, 51
value
column, 60, 62
volume, 19
Volume
PUBLICATIONS Table, 44

W

warning, 59
web site, 8
Weight
TREATMENT_COURSES Table, 46
what data should be submitted, 1
when data should be submitted, 6
who should submit data, 1

Y

year, 19
Year
PUBLICATIONS Table, 44

Z

zip code, 2, 19
Zip_Code
PATIENTS Table, 44